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ABSTRACT
Engineering Cell-Free Protein Expression Systems for
Biotherapeutics and Biosensing
John Porter Hunt
Department of Chemical Engineering, BYU
Doctor of Philosophy
Therapeutic proteins have become a cornerstone of modern medicine since the FDA
approval of recombinant human insulin in 1982. Likewise, biosensors transform chemical
detection and disease diagnostics by identifying biomarkers, chemical contaminants, and infective
agents. Long-standing methods for creating therapeutics and biosensors employ whole cells such
as Escherichia coli (E. coli). Alternatively, cell-free protein synthesis (CFPS) employs the
enzymatic reactions necessary for protein production and biosensing within a cell, but in an
engineered reactor environment facilitating unprecedented access to and control over biochemical
machinery, preservation by cryodesiccation for portable deployment, and functionality in
cytotoxic applications.
This dissertation reports advances in an E. coli CFPS production platform toward creating
therapeutic proteins by this means. First, an endotoxin-free CFPS platform is created by optimizing
fermentation and cell-extract harvest of an endotoxin-free E. coli strain. Next, liquid cell growth
culture media is specially formulated to change chemical composition during cell culture and
provide a streamlined method for producing high-yielding, endotoxin-free E. coli CFPS. Then,
novel CFPS bioreactor formats are developed and mathematically validated which employ
“hydrofoam” and oxygen to increase therapeutic protein production yield.
Additionally, advances are reported in CFPS biosensing technology. First, a chimeric
fusion protein incorporating the ligand binding domain of the human estrogen receptor is expressed
in CFPS to detect estrogenic chemicals in the presence of human blood and urine. Next, the
molecular mechanism of this protein construct is elucidated and the assay readout is optimized
with mathematical simulations and CFPS. Then, CFPS is metabolically engineered to create a
biosensor of L-glutamine, the most abundant amino acid in the body.
Finally, this dissertation reports the development of a synergistic platform for potentially
treating Acute Lymphoblastic Leukemia wherein CFPS is engineered to both produce the
therapeutic protein crisantaspase and assess its activity in the presence of human serum for
improved, potentially even personalized treatment of the disease. It is anticipated that the advances
reported herein will contribute to the utility of in vitro or cell-free protein synthesis for therapeutic
and diagnostic applications.
Keywords: cell-free protein synthesis, cell-free, protein synthesis, CFPS, biotherapeutic,
biologic, endotoxin, hydrofoam, michaelis-menten kinetics, biosensor, hormone biosensor, cellfree biosensor, endocrine disrupting chemical, glutamine, glutamine assay, acute lymphoblastic
leukemia, asparaginase, crisantaspase, erwinaze, point of care.
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INTRODUCTION

Custom protein synthesis is a 50 billion USD industry that impacts most parts of human
lives, including and the lifesaving therapeutics many people require1. The original workhorse of
custom recombinant protein synthesis is Escherichia coli, which remains the most cost-effective
method and can produce many complex proteins (including insulin2 and antibodies3). Other
synthesis chassis including yeast and mammalian cells have been developed for proteins requiring
advanced assembly and post-translational modifications such as glycosylation and lipidation4,5.
Significantly, cell-free protein expression systems have introduced many attractive
advantages to protein synthesis technology6. Because the reaction environment is not confined
within a cell wall, proteins can be expressed from rapidly-produced PCR gene products7, and
dynamic optimization of the reaction environment becomes possible8,9. Changes in reaction
conditions such as redox potential, pH, hydrophobicity, and temperature enable expression of a
variety of active proteins that are often difficult to produce in vivo. Notable examples include
cytotoxic proteins10, membrane proteins11,12, metallic holoenzymes13,14, and virus-like particles1517

. Cell-free protein synthesis (CFPS) reactions also allow the incorporation of unnatural, even

toxic18 amino acids19-23.
Cell-free protein synthesis (CFPS) is also an emerging biosensing platform with manifold
promising applications24-28. The open transcription-translation reaction environment facilitates
exquisite system optimization and control, and CFPS biosensors have been engineered to operate
1

on the transcription, translation, and protein-folding levels29. Sensing platforms formulated from
E. coli lysates leverage the robustness of bacterial gene expression, can be lyophilized to create
portable indicators30-33, and have demonstrated utility in a variety of environmental and biological
sample matrices25,34. Compared with their microbial counterparts, CFPS biosensors eliminate
sample transport limitations as well as the risk of releasing genetically modified microbes35.
Additionally, they enable more rapid readouts and detection in matrices that are toxic to microbes.
Through this work, cell-free protein synthesis technology is engineered and enhanced
toward two classes of applications: 1) Biotherapeutic production and 2) Clinically relevant
biosensing. The first three chapters describe three technological advances which increase the utility
of cell-free protein synthesis toward biotherapeutic production: 1) The use of ClearColiTM cell
extract for endotoxin-free cell-free protein synthesis, 2) The development of a streamlined method
for production of ClearColiTM cell extract, and 3) The invention and validation of “hydrofoam”
and oxygen bioreactors for enhanced cell-free synthesis of biotherapeutics. The following three
chapters describe technological advances which enabling biosensing in human samples using
CFPS: 1) The development of a cell-free biosensor for estrogenic molecules, 2) Optimization and
mechanistic discoveries of hormone biosensors with CFPS, and 3) Engineering CFPS to create a
biosensor of L-glutamine. The next chapter demonstrates both classes of CFPS utility, production
and biosensing, and describes how E. coli CFPS was engineered to produce a therapeutic protein
and assay that protein’s circulating therapeutic activity.
This dissertation is an adaptation of publications which JPH authored or coauthored as
described in each chapter. As such, literature review, motivation, and a more thorough introduction
to each topic is included at the beginning of each chapter. Introductions and adaptations are
summarized in the outline below. This introduction is taken from the journal article by J. Porter
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Hunt, Seung Ook Yang, Kristen M. Wilding, and Bradley C. Bundy titled, “The Growing Impact
of Lyophilized Cell-free Protein Expression Systems”, Bioengineered, 2017, Vol. 8, No. 4, 325–
330, https://doi.org/10.1080/21655979.2016.1241925 and the article by J. Porter Hunt, R. Jordan
Barnett, Hannah Robinson, Mehran Soltani, J. Andrew D.Nelson, and Bradley C.Bundy entitled,
“Rapid sensing of clinically relevant glutamine concentrations in human serum with metabolically
engineered E. coli-based cell-free protein synthesis” published in Journal of Biotechnology, 2021,
Vol. 325, 389-394, https://doi.org/10.1016/j.jbiotec.2020.09.011.

Chapter 2: ClearColiTM Cell-free Protein Synthesis for Endotoxin-free Biotherapeutic
Production
This chapter is an adaptation from the journal article by Kristen M. Wilding, J. Porter Hunt,
Joshua W. Wilkerson, Parker J. Funk, Rebecca L. Swensen, William C. Carver, Michael L.
Christian, and Bradley C. Bundy titled, “Endotoxin-free E. coli-based cell-free protein synthesis:
Pre-expression endotoxin removal approaches for on-demand cancer therapeutic production,”
published

March

2019

in

Biotechnology

Journal,

14:

1800271,

https://doi.org/10.1002/biot.201800271.
Approximately one third of protein therapeutics are produced in Escherichia coli, targeting
a wide variety of diseases. However, due to immune recognition of endotoxin (a lipid component
in the E. coli cell membrane), these protein products must be extensively purified before
application to avoid adverse reactions such as septic shock. E. coli‐based cell‐free protein synthesis
(CFPS), which has emerged as a promising platform for the development and production of
enhanced protein therapeutics, provides a unique opportunity to remove endotoxins prior to protein
expression. In this work, we report the first application of E. coli strain ClearColiTM to prepare
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highly active endotoxin-free cell extract. Additionally, production of the acute lymphoblastic
leukemia therapeutic crisantaspase from endotoxin‐free ClearColi extract is demonstrated.

Chapter 3: Autoinduction Media for Streamlined Endotoxin-free Cell Extract
Preparation
This chapter is an adaptation from the journal article by J. Porter Hunt, Emily Long Zhao,
Mehran Soltani, Madison Frei, J. Andrew D. Nelson, Bradley C. Bundy titled, “Streamlining the
preparation of “endotoxin-free” ClearColi cell extract with autoinduction media for cell-free
protein synthesis of the therapeutic protein crisantaspase” published in Synthetic and Systems
Biotechnology,

December

2019,

Volume

4,

Issue

4,

,

Pages

220-224,

https://doi.org/10.1016/j.synbio.2019.11.003.
An “endotoxin-free” E. coli-based cell-free protein synthesis system has been reported to
produce therapeutic proteins rapidly and on-demand. However, preparation of the most complex
CFPS reagent – the cell extract – remains time-consuming and labor-intensive because of the
relatively slow growth kinetics of the endotoxin-free ClearColiTM BL21(DE3) strain. Here, we
report a streamlined procedure for preparing E. coli cell extract from ClearColiTM using autoinduction media. In this work, the term auto-induction describes cell culture media which
eliminates the need for manual induction of protein expression. Culturing ClearcoliTM cells in
autoinduction media reduces the hands-on time required during extract preparation by more than
90%, and the resulting “endotoxin-free” cell extract maintained the same cell-free protein synthesis
capability as extract produced with traditional induction as demonstrated by the high-yield
expression of crisantaspase, an FDA approved leukemia therapeutic. It is anticipated that this work
will lower the barrier for researchers to enter the field and use this technology as the method to
produce endotoxin-free E. coli-based extract for CFPS.
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Chapter 4: Enhanced Cell-free Oxygen Transport through Hydrofoam and Oxygen
Headspace Bioreactors
This chapter is an adaptation from the journal article by J. Andrew D. Nelson, R. Jordan
Barnett, J. Porter Hunt, Isaac Foutz, Meagan Whelton, and Bradley C. Bundy entitled, “Hydrofoam
and oxygen headspace bioreactors improve cell-free therapeutic protein production yields through
enhanced oxygen transport,” published by Biotechnology Progress September 2020,
https://doi.org/10.1002/btpr.3079.
Protein therapeutics are powerful weapons against diabetes, cancers, growth disorders, and
many other diseases. However, availability is limited due to cost and complications of production
from living organisms. To make life-saving protein therapeutics more available to the world, the
possibility of magistral or point-of-care protein therapeutic production has gained focus. The
recent invention and optimization of lyophilized “cell-free” protein synthesis reagents and its
demonstrated ability to produce highly active versions of FDA-approved cancer therapeutics have
increased its potential for low-cost, single-batch, magistral medicine. Here we present for the first
time the concept of increased oxygen mass transfer in small-batch, cell-free protein synthesis
(CFPS) reactions through air-water foams. These “hydrofoam” reactions increased CFPS yields
by up to 100%. Contrary to traditional protein synthesis using living organisms, where foam
bubbles cause cell lysis and production losses, hydrofoam CFPS reactions are “cell-free” and better
tolerate foaming. Simulation and experimental results suggest that oxygen transfer is limiting in
even small volume batch CFPS reactors and that the hydrofoam format improved oxygen transfer.
This is further supported by CFPS reactions achieving higher yields when oxygen gas replaces air
in the headspace of batch reactions. Improving CFPS yields with hydrofoam reduces the overall
cost of biotherapeutic production, increasing availability to the developing world. Beyond protein
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therapeutic production, hydrofoam CFPS could also be used to enhance other CFPS applications
including biosensing, biomanufacturing, and biocatalysis.

Chapter 5: Developing a Cell-free Biosensor of Estrogenic Molecules
This chapter is an adaptation from the journal article by Amin S.M. Salehi, Seung Ook
Yang, Conner C. Earl, Miriam J. Shakalli Tang, J. Porter Hunt, Mark T. Smith, David W. Wood,
Bradley C. Bundy entitled, “Biosensing estrogenic endocrine disruptors in human blood and urine:
A RAPID cell-free protein synthesis approach,” published in Toxicology and Applied
Pharmacology,

15

April

2018,

Volume

345,

Pages

19-25,

https://doi.org/10.1016/j.taap.2018.02.016.
Many diseases and disorders are linked to exposure to endocrine disrupting chemicals
(EDCs) that mimic the function of natural estrogen hormones. Here we present a Rapid Adaptable
Portable In-vitro Detection biosensor platform (RAPID) for detecting chemicals that interact with
the human estrogen receptor β (hERβ). This biosensor consists of an allosteric fusion protein,
which is expressed using cell-free protein synthesis technology and is directly assayed by a
colorimetric response. The resultant biosensor successfully detected known EDCs of hERβ (BPA,
E2, and DPN) at similar or better detection range than an analogous cell-based biosensor, but in a
fraction of the time. We also engineered cell-free protein synthesis reactions with RNAse
inhibitors to increase production yields in the presence of human blood and urine. The RAPID
biosensor successfully detects EDCs in these human samples in the presence of RNAse inhibitors.
Engineered cell-free protein synthesis facilitates the use of protein biosensors in complex sample
matrices without cumbersome protein purification.
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Chapter 6: Mechanism and Simulation-guided Optimization of Cell-free Hormone
Biosensor Assay
This chapter is an adaptation from the journal article by J. Porter Hunt, Jackelyn Galiardi,
Tyler Free, Seung Ook Yang, Daniel Poole, Joshua L. Anderson, David W. Wood, Bradley C.
Bundy titled “Mechanistic discoveries and simulation-guided assay optimization of portable
hormone biosensors with cell-free protein synthesis” in preparation for submission to
Biotechnology Journal.
Nuclear receptors influence nearly every system of the body and our lives depend on
correct nuclear receptor signaling. Thus, a key environmental and pharmaceutical quest has
emerged from the effort to identify and detect chemicals which interact with nuclear hormone
receptors, including endocrine disrupting chemicals, therapeutic receptor modulators, and natural
hormones. Previously reported biosensors of nuclear hormone receptor ligands facilitate rapid and
potentially portable detection of nuclear receptor ligands using cell-free protein synthesis (CFPS).
In this work, the advantages of CFPS are further leveraged and combined with mathematical
simulations to study and optimize this powerful protein biosensor, ultimately lengthening the
assay’s readable window by three-fold and improving sensor signal strength by two-fold. The
mathematical and experimental results obtained with this approach provide critical insight for
engineering rapid and field-deployable biosensors of endocrine disrupting chemicals, therapeutic
receptor modulators, and natural hormones.

Chapter 7: Engineering Cell-free Metabolism for Detection of L-Glutamine in
Human Serum
This chapter is an adaptation from the journal article by J. Porter Hunt, R. Jordan Barnett,
Hannah Robinson, Mehran Soltani, J. Andrew D.Nelson, and Bradley C.Bundy entitled, “Rapid
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sensing of clinically relevant glutamine concentrations in human serum with metabolically
engineered E. coli-based cell-free protein synthesis” published in Journal of Biotechnology,
Volume 325, January 2021, Pages 389-394, https://doi.org/10.1016/j.jbiotec.2020.09.011.
Bioavailable L-glutamine (Gln) is critical for metabolism, intestinal health, immune
function, and cell signaling. Routine measurement of serum Gln concentrations could facilitate
improved diagnosis and treatment of severe infections, anorexia nervosa, chronic kidney disease,
diabetes, and cancer. Current methods for quantifying tissue Gln concentrations rely mainly on
HPLC, which requires extensive sample preparation and expensive equipment. Consequently,
patient Gln levels may be clinically underutilized. Cell-free protein synthesis (CFPS) is an
emerging sensing platform with promising clinical applications, including detection of hormones,
amino acids, nucleic acids, and other biomarkers. In this work, in vitro E. coli amino acid
metabolism is engineered with methionine sulfoximine to inhibit glutamine synthetase and create
a CFPS Gln sensor. The sensor features a strong signal-to-noise ratio and a detection range ideally
suited to physiological Gln concentrations. Furthermore, it quantifies Gln concentration in the
presence of human serum. This work demonstrates that CFPS reactions which harness the
metabolic power of E. coli lysate may be engineered to detect clinically relevant analytes in human
samples. This approach could lead to transformative point-of-care diagnostics and improved
treatment regimens for a variety of diseases including cancer, diabetes, anorexia nervosa, chronic
kidney disease, and severe infections.

Chapter 8: Biomanufacturing and Biosensing for Treatment of Acute Lymphoblastic
Leukemia with Cell-free Protein Synthesis
This chapter is an adaptation from the article by J. Porter Hunt, Kristen M. Wilding, R.
Jordan Barnett, Hannah Robinson, Mehran Soltani, Jae Eun Cho, Bradley C. Bundy entitled,
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“Engineering cell-free protein synthesis for high-yield production and human serum activity
assessment of asparaginase – toward on-demand treatment of acute lymphoblastic leukemia”
published

in

Biotechnology

Journal,

January

2020,

15,

1900294,

https://doi.org/10.1002/biot.201900294.
Acute Lymphocytic Leukemia (ALL) is a common childhood cancer in the United States
with over 6000 new cases diagnosed each year. Administration of bacterial asparaginases has
improved survival rates to nearly 80%, however these therapeutics have high incidence of
immunological neutralization and serum activity must be monitored for most effective treatment
regimens. Here, we demonstrate a 72% improvement in cell-free protein synthesis (CFPS) of FDA
approved L-asparaginase (crisantaspase) by employing an aspartate-fed-batch reactor format. We
also present a CFPS-based asparaginase activity assay as a tool for therapeutic regimentation and
production quality control. This work suggests that shelf-stable and low-cost E. coli-based CFPS
reactions may be employed on-demand to 1) synthesize biologics on-site for patient
administration, 2) verify biologic activity for dosage calculations, and 3) monitor therapeutic
activity in human serum during the treatment regimen. The combination of both therapeutic
production and activity assessment introduces a concept of synergistic utility for bacterial cell
lysates in modern medical treatment. Indeed, recent work with CFPS biosensors supports a nottoo-distant future when shelf-stable E. coli CFPS systems are used to diagnose, treat, and monitor
treatment of diseases in the clinical setting.
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2

CLEARCOLI CELL-FREE PROTEIN SYNTHESIS FOR ENDOTOXIN-FREE
BIOTHERAPEUTIC PRODUCTION

This chapter is an adaptation from the journal article by Kristen M. Wilding, J. Porter Hunt,
Joshua W. Wilkerson, Parker J. Funk, Rebecca L. Swensen, William C. Carver, Michael L.
Christian, and Bradley C. Bundy titled, “Endotoxin-free E. coli-based cell-free protein synthesis:
Pre-expression endotoxin removal approaches for on-demand cancer therapeutic production,” by
Wilding, K.M., Hunt, J.P., Wilkerson, J.W., Funk, P.J., Swensen, R.L., Carver, W.C., Christian,
M.L. and Bundy, B.C., published March 2019 in Biotechnology Journal, 14: 1800271,
https://doi.org/10.1002/biot.201800271.
Kristen Wilding, PhD is the primary author of this work and, as the senior graduate student,
she directed this work and was its most significant contributor. The contribution of JPH to this
manuscript was primarily the development of optimal fermentation conditions for ClearColi
extract preparation with the help of undergraduates Parker Funk and Joshua Wilkerson. This
fermentation research was an essential component of the work and a fundamental pillar for
endotoxin-free, E. coli-based cell-free protein synthesis. A significant portion of this work is
presented in this dissertation to provide context for the contributions of JPH, who is very grateful
to Dr. Wilding for the opportunity to contribute.
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Introduction
The past few decades have seen a dramatic increase in the number of recombinant protein
therapeutics developed to target a wide variety of diseases such as cancer, arthritis, and diabetes.
Approximately one third of all these products are produced in Escherichia coli36,37. The E. coli
platform is attractive for therapeutic production due to its low cost and rapid growth kinetics.
However, like other gram-negative bacteria, E. coli produce high levels of lipopolysaccharide
(LPS), or endotoxin, during cell growth, division, and lysis. Human exposure to endotoxin
activates an immune response and can result in septic shock36,38,39. Therefore, therapeutics
produced in E. coli must be extensively purified to remove endotoxin to extremely low levels
before administration40. This additional processing and quality control adds to the cost of protein
therapeutic production, with downstream processing in general accounting for 45–92% of total
manufacturing costs41. The removal process can result in poor protein recovery, reduced protein
activity, and the introduction of contaminants which often necessitates optimization for each
individual product36,338,41,42. One potential solution is to use cell-free protein synthesis (CFPS),
where the biological machinery necessary for transcription and translation is harvested from cells
and activated in vitro. This approach to protein synthesis provides the unique potential to shift
several processing steps upstream, such as cell lysis and separation. Thus, the system provides an
opportunity for endotoxin removal prior to protein synthesis. This pre-expression endotoxin
removal could potentially simplify or eliminate downstream endotoxin removal steps. Preexpression endotoxin removal would be especially important for the emerging application of
lyophilized CFPS technology for on-demand, deployable therapeutic synthesis, which could
enable rapid production of personalized therapeutics or therapeutics in response to a pandemic
threat43-46. Here, we evaluate three methods of preexpression endotoxin removal from CFPS

11

systems. We report that conventional methods of endotoxin removal from clarified E. coli cell
lysate, or cell-free extract, show promise, but significant cost and engineering is necessary to make
these methods viable. By contrast, optimized production of cell extract from ClearColi (an LPSfree genetically engineered BL21 DE3 E. coli strain) produced consistently high yields of protein
without the need for specific endotoxin removal steps. Further, we demonstrate production of a
clinically relevant FDA-approved cancer therapeutic, crisantaspase, from low endotoxin and
endotoxin-free E. coli cell-free extract.

Materials and Methods

2.2.1

Extract Preparation

Cell extracts were made using either the E. coli BL21 StarTM (DE3) strain (BL21 StarTM
(DE3)) (Invitrogen, Carlsbad, CA) or ClearColi® BL21 (DE3) chemically competent cells
(Lucigen, Middleton, WI). Each extract was grown using sterile technique without the addition of
antibiotic. Standard BL21 StarTM (DE3) extract was produced as described previously1. Briefly,
overnight cultures of 5 mL of LB were inoculated into 100 mL of 2xYT and incubated at 37°C
and 280 rpm until an OD600 of 2. The 100 mL culture was then inoculated into a 2.5 L shake flask
containing 900 mL of 2xYT. T7 RNA Polymerase expression was induced with 1 mM IPTG at an
OD600 0.5-0.7, and cells were harvested in mid-long phase (around OD600 2.5 – 3.5 in this work).
Cells were then harvested, homogenized using an Avestin Emulsiflex-B15 homogenizer, and
prepared as previously described2. ClearColi® extracts were prepared similarly, with the following
modifications. First, TB media with 5 g/L or 10 g/L NaCl was used in place of 2xYT to support
higher cell densities of ClearColi® growth. Second, a 100 mL culture was inoculated directly from
a frozen glycerol stock of the ClearColi® BL21 DE3 cells and the culture was allowed to grow
12

overnight, reaching an OD of 2-3. Cells were induced at a variety of OD600, varying from 0.1 –
0.7, and harvested at a variety of OD600 ranging from 0.6 – 3.5. Cells were harvested, lysed, and
otherwise prepared according to the same procedure as the standard BL21 StarTM (DE3) cells.

2.2.2

Fermentation Media Optimization

Media optimizations were performed in two sets. For the first set, 5 mL LB-Miller media
was inoculated from a frozen glycerol stock of ClearColiTM BL21 DE3 Electrocompetent cells
(Lucigen) and grown overnight. The 5 mL growths were then each used to inoculate 100 mL of
the test media in a 500 mL shake flask. The shake flask was incubated at 37°C and 280 rpm, with
OD600 measurements taken using a Synergy-MX every 30-60 minutes. Media tested included LBMiller with 10-20 g/L total NaCl, 2xYT with 5-20 g/L total NaCl, and TB with 0-15 g/L total NaCl.
For the second set, LB-Miller with 10-20 g/L total NaCl, 2xYT with 5-20 g/L total NaCl, and TB
with 0-20 g/L total NaCl were each tested. A 10 mL culture of each medium was inoculated to an
initial OD600 of OD600 of <0.05 in 50 mL conical centrifuge tubes and incubated at 37 °C and
280 rpm. OD600 measurements were taken in duplicate every 60-90 minutes for 10 hours.

Results and Discussion
An alternative to pre-expression endotoxin removal for preparation of an endotoxin-free
CFPS system is to prepare extract from an E. coli strain that is inherently endotoxin-free. Recently
researchers have developed such a strain, the genetically modified BL21 DE3 E. coli strain
ClearColi (ΔgutQ, ΔkdsD, ΔlpxM, ΔpagP, ΔlpxP, ΔeptA). In the ClearColi membrane lipid, the
core oligosaccharide and two of the lipid chains from the LPS have been eliminated, rendering the
lipid unrecognizable to the toll-like receptor 4 (TLR4) complex responsible for the endotoxin
reaction in humans (Figure 2-1A) 36,47,48. This strain has therefore been shown in multiple studies
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to be “endotoxin free” and can be used to produce therapeutics without downstream endotoxin
removal steps36,37,48–50. Here we report the first use of ClearColi to make cell-extract for CFPS and
report its viability in cell-free systems. The ClearColi extract preparation procedure differs slightly
from that of standard extract due to the altered characteristics of the ClearColi cells. ClearColi
cells are reportedly more sensitive to osmolarity, grow at approximately half the rate of regular
BL21 cells, and reach lower final densities36, 51. Gene expression in bacteria changes dramatically
with growth rate and cell phase, making induction and harvest points important parameters when
preparing extract for CFPS52. Using the lab-scale shake-flask fermentation approach with
commonly used media, induction, and harvest protocols, the protein production yields from
ClearColi extracts were 20% of regular BL21 DE3 extracts. Therefore, in order to create a highyielding ClearColi extract, both the effect of media type on the ClearColi growth and the effect of
induction and harvest times on cell-free extract activity were investigated.

Figure 2-1. ClearColi extract preparation. A) Schematic of E. coli lipid A (LPS) versus ClearColi
lipid IVA. Hexagons represent various sugars: gray ¼ Dgalactose, orange ¼ D-glucose, green ¼ lglycerol-D-manno-heptose, blue ¼ 3-deoxy-D-manno-oct-ulosonic acid. Yellow circle represents
phosphate, light blue oval represents phosphoethanolamine; B) Growth curves for standard E. coli
BL21 StarTM (DE3) in 2xYT media and ClearColi in TB with 5 and 10 g L1 added NaCl. Smooth lines
represent Verhuslt-Pearl growth equation fits to the data; C) sfGFP yield from ClearColi extracts
versus induction/harvest OD600; D) Comparison of sfGFP yield from CFPS reactions using either
BL21 StarTM (DE3) extract versus induction/harvest optimized ClearColi extract fermented with TB
media, n 3, error bars represent one standard deviation.
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2.3.1

Media Optimization

Media Optimization Allows Higher Growth Rates and Cell Densities During Extract
Preparation Three different media formulations and varying levels of NaCl were tested: LB-Miller
(the recommended media for ClearColi protein preparations), 2xYT media (reported to produce
high-yielding CFPS extracts), and TB media (which supports E. coli growth to higher cell
densities) 51,53. The three media formulations were evaluated at increasing NaCl levels, as enhanced
ClearColi growth has been suggested at higher osmolarity and ionic strength. Thus, NaCl was
added to LB, 2xYT, and TB media ranging from original concentration in the media (10 gm/L for
LB-Miller, 5 gm/L for 2xYT, and 0 gm/L for TB) up to 20 gm/L. Results indicated that TB media
consistently facilitated faster final growth rates and higher cell densities, and that increasing NaCl
concentration beyond an additional 5 g per L did not significantly improve cell growth rates and
densities (Figure 2-2). Therefore, TB media with an additional 5 or 10 g L1 NaCl was used to grow
ClearColi for cell-free extract preparation. While the ClearColi growth rate with TB was
significantly faster than other media formulations, it remained lower than BL21 (DE3) (0.72 0.12
vs. 1.48 0.25 h1 characteristic growth rate as determined by the Verhulst-Pearl equation) (Figure
2-2). A comparison of the ClearColi growth rate to BL21 (DE3) is shown in Figure 2-1A.
Optimization of IPTG induction timing for ClearColi extract production capacity
The induction and harvesting OD600 was next optimized for ClearColi extract preparation.
IPTG induction is required for T7 RNA polymerase production and induction at 0.5 OD600 with
harvest at mid to late log phase has previously been shown to be optimal53. The impact of induction
and harvest OD600 on CFPS activity of ClearColi extract was assessed (Figure 2-1C). The highest
yielding ClearColi extracts were induced just before log phase (OD600 0.6) and harvested in midlog phase (OD600 2–3, 5–7 g cell/L media). Interestingly, comparable CFPS yields could be
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obtained when extracts were induced earlier (OD600 0.1) and harvested earlier (OD600 0.6–2.5, 2–
5 g cells/L media), potentially because these cells are earlier in the growth phase and enriched with
ribosomes. The sfGFP production yields of these highest performing ClearColi extracts were
comparable to standard BL21 yields, at about 80–90% of the yields of standard extract (Figure
2-1D).

Figure 2-2 Media Optimization. A&C: Growth curves and final instantaneous growth rates from
media optimization for 100 mL growths in 500 mL shake flasks, where orange curves are grown in
LB media, blue curves represent growths in 2xYT media, and green curves represent growths in TB
media. Note that TB media with 5 g/L or 10 g/L NaCl consistently reaches the highest OD600 during
the growth period, and TB with >0 g/L NaCl has highest final instantaneous growth rates (n=1-3);
B&D: Growth curves and final instantaneous growth rates (average of n=2) from media optimization
for 10 mL growths in 50 mL falcon tubes, where orange curves are grown in LB media, blue curves
represent growths in 2xYT media, and green curves represent growths in TB media. Note that TB
media again reaches the greatest OD600 and is consistently among the highest final instantaneous
growth rates. Oxygen transfer in the 50 mL falcon tubes may have been limiting, considering the lack
of air flow through the cap, which may explain some of the discrepancies in final OD600 and
instantaneous growth rates between the 100 mL and 10 mL growths.
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2.3.2

High Titers of Crisantaspase from Endotoxin-free Cell-free Protein Synthesis

Crisantaspase (ErA) is an asparaginase derived from Erwinia chrysanthemi bacteria which is FDAapproved as a secondary treatment for acute lymphocytic leukemia in patients who have developed
immune responses against the primary treatment, E. coli-derived asparaginase54. To meet
restrictions for intravenous administration, residual endotoxin in ErA must not exceed 5 EU kg1
patient/h55. Therefore, reducing the initial endotoxin contamination of the sample could
significantly simplify downstream purifications for this drug. To investigate this, active ErA was
produced using the standard BL21 extract and ClearColi extract, which is the first time to our
knowledge that ErA has been produced using CFPS. ErA yields for both cell-free systems is shown
in Figure 2-3A. ErA produced in these reactions was purified via a single Ni-NTA affinity column,
and the endotoxin content of each sample was evaluated using the widely used limulus ameobocyte
lysate (LAL) assay (Figure 2-3B). A single Ni-NTA spin column treatment reduced the LAL
reactivity of ErA by greater than 1000-fold for ErA produced using standard BL21 DE3 extract,
and by 20 000-fold for ErA produced from the ClearColi extracts. The 10-fold higher reduction of
LAL reactivity from the ClearColi CFPS-derived ErA compared to the other extracts is consistent
with previous reports that the absence of the oligosaccharide in lipid IVA makes it easier to remove
than standard LPS1. The residual LAL activation from the ClearColi derived product is likely due
to the previously reported nonspecific nature of the LAL assay, which has been reported to react
with a broader spectrum of lipids than does the human immune system36,49. ClearColi extracts
produced 70% as much ErA as standard BL21 during short reaction times, and extended reaction
times enabled comparable yields from both BL21 and ClearColi extracts, at up to 1 mg/mL ErA.
Analogous to culture growth rates, CFPS production rates in ClearColi appear to be slower than
BL21*(DE3). The higher yield of the ClearColi-derived extract, coupled with the simplicity of
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extract preparation and the reported activity of the lipid IVA as an antagonist rather than an agonist
for endotoxin response in humans, makes the cell-free ClearColi system a promising approach to
simplify purification requirements of deployable, on-demand therapeutic synthesis48. In addition,
the ErA produced in the new ClearColi extract retained the same activity of that produced in BL21
(DE3) extract (Figure 2-3C).

Figure 2-3: CFPS ErA expression, purification, and activity. A. Expression of ErA by both
BL21*DE3 and ClearColi CFPS. B. Endotoxin content determined by LAL kinetic turbidimetric
assay of ErA samples purified by His-tag purification with single pass Ni-NTA spin columns from
CFPS reactions using BL21 Star (DE3) extract and ClearColi extract. C. therapeutic activity of ErA
expressed with both BL21*DE3 and ClearColi CFPS.

Conclusion
The presence of endotoxin is a limitation of E. coli-based CFPS systems and threatens
septic shock if not adequately removed during purification. Highly active and inherently
endotoxin-free extract was produced using the ClearColiTM cell strain after extract preparation
procedures were modified to account for the altered growth kinetics of this strain. In addition,
consistent production of significant amounts of the clinically relevant therapeutic protein
crisantaspase (ErA) was demonstrated using this system. This system is inherently endotoxin-free
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and allows greater production yield than pre-expression endotoxin removal approaches. Thus,
ClearColi CFPS is the platform recommended by the authors for achieving endotoxin-free CFPS.
The presented platform improves upon the endotoxin-free in vivo production enabled by the
ClearColi strain by shifting steps such as fermentation and lysis upstream to enable rapid
therapeutic synthesis in a ready-to-use, open format which is more amenable to deployable, ondemand production. The presented platforms are an important step toward on-site therapeutic
production, potentially allowing rapid and portable synthesis of therapeutic proteins without the
need for complex downstream purification.
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3

AUTOINDUCTION MEDIA FOR STREAMLINED ENDOTOXIN-FREE CELL
EXTRACT PREPARATION

This chapter is an adaptation from the article by J. Porter Hunt, Emily Long Zhao, Mehran
Soltani, Madison Frei, J. Andrew D. Nelson, Bradley C. Bundy entitled, “Streamlining the
preparation of “endotoxin-free” ClearColi cell extract with autoinduction media for cell-free
protein synthesis of the therapeutic protein crisantaspase” published in Synthetic and Systems
Biotechnology,

December

2019,

Volume

4,

Issue

4,

Pages

220-224,

https://doi.org/10.1016/j.synbio.2019.11.003. The idea of using autoinduction media for cell
extract preparation preceded JPH in the Bundy lab, and the role of JPH in this work included
conceiving the scope, designing the experiments, conducting experiments, writing the manuscript,
and responding to reviewers, with significant contributions to all of the above from Emily L. Zhao,
Mehran Soltani, Madison Frei, and J. Andrew D. Nelson.

Introduction
The invention of low-cost, lyophilized, and shelf-stable reagents for cell-free protein
synthesis (CFPS) has the potential to transform how therapeutic proteins are produced56,57. This
technology could enable distributed on-site production of specialized and even personalized
protein therapeutics anywhere58,59. Recently, researchers have also developed an on-demand cellfree expression platform using an engineered E. coli strain reported elsewhere to be “endotoxinfree”60,61, and this platform was used to produce a complex cytotoxic FDA-approved therapeutic
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protein62,63. This advancement combines the low-cost, high-yield performance of E. coli cell
lysates with endotoxin-free production traditionally only achieved with eukaryotic cell lysates6466

, and demonstrates that transformative, on-site protein therapeutic production at low cost is closer

to becoming a reality67,68.
One challenge to employing this endotoxin-free CFPS platform arises from the slow
growth kinetics of the ClearColiTMBL21(DE3) strain, which require extended monitoring of cell
growth during production of the most complex CFPS reagent – the cell extract. Here, we introduce
a new fermentation procedure for preparing E. coli-based CFPS extract that contains T7 RNA
Polymerase (T7 RNAP) using auto-induction media. We successfully apply this procedure to
create highly active BL21 StarTM(DE3) and endotoxin-free ClearColiTM BL21(DE3) cell extract,
then use auto-inducted endotoxin-free cell extract to produce the therapeutic protein crisantaspase.
Erwinaze, the commercial form of crisantaspase has lamentably been out of stock multiple times
in recent years, and was out of stock while this manuscript was reviewed. This fact highlights the
need for on-demand/magistral strategies to produce this critical therapeutic and the value of this
streamlined workflow for cell extract production. We anticipate that it will enable new researchers
to enter the field of endotoxin-free CFPS. Our hope is that streamlined protocols for endotoxinfree CFPS systems will ultimately help address the unmet need for global accessibility to protein
therapeutics at reasonable costs.
While potential applications of endotoxin-free CFPS have primarily been focused on
producing therapeutic proteins using CFPS, the presented streamlined technology also has
application to other CFPS products including biosensors69-71, gene circuits72-74, biocatalysts75-77,
vaccines78,79, protein-polymer conjugates80, and uniquely functionalized proteins with noncanonical amino acids81-83.
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Figure 3-1 depicts the development of CFPS extract preparation processes, starting with
the seminal method of Pratt84 that was further developed in the J.R. Swartz lab at Stanford up to
this current work which builds upon these methods. Advances include the ability to omit the
dialysis step post lysis85, the production of T7 RNAP during fermentation86, and the introduction
of auto-induction media in this work.

Figure 3-1: Pictorial representation of streamlining advancements in extract preparation procedures
upon which this work builds.

Materials and Methods

3.2.1

Investigating Induction Timing in Auto-Induction Media

Auto-induction media was adapted from the protocol reported by Studier87. Specifically,
solutions of 4% lactose, 10% glucose, 80% glycerol, 1 M MgSO4, 1000x trace metals (50 mM
FeCl3, 20 mM CaCl2, 10 mM each of MnCl2 and ZnSO4, and 2 mM each of CoCl2, CuCl2, NiCl2,
Na2MoO4, Na2SeO3, and H3BO3 in 60 mM HCl) and 50x Buffer M (1.25 M Na2HPO4, 1.25 M
KH2 PO4, 2.5 M NH4Cl, and 250 mM Na2SO4) were filter sterilized. Solutions of 1% tryptone, and
0.5% yeast extract were autoclaved. These solutions were combined with ultra-pure water to
achieve final concentrations of 0.2% w/v lactose, 0.05% w/v or 1% w/v glucose, 0.5% v/v glycerol,
25 mM Na2HPO4, 25 mM KH2 PO4, 50 mM NH4Cl, 5 mM Na2SO4, 1% w/v tryptone, 0.5% w/v
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yeast extract, and trace metals at the above concentrations diluted 1000x (0.05 µM FeCl3, etc.).
(See Studier auto-induction media “ZYM-5052”87. For routine extract preparation with
autoinduction media, lactose, glycerol, and glucose may be combined and autoclaved). Calcium
competent BL21 StarTM(DE3) and ClearColiTM BL21(DE3) cells were transformed with pY71sfGFP88. Overnight (~16 hrs) starter cultures of E. coli BL21 StarTM(DE3) (Invitrogen, Carlsbad,
CA), and BL21 StarTM(DE3)-pY71-sfGFP were grown in LB-Miller media (1% w/v tryptone, 0.5%
w/v yeast extract, 1% w/v sodium chloride) at 37°C and 280 rpm in 16x100 mm test tubes (Corning
Inc., Corning, NY). 1 mL overnight culture was added to 100 mL duplicate auto-induction media87
with either 0.05 or 1% w/v final glucose concentrations. Kanamycin was added to pY71 cell strains
to a final concentration 40 ug/mL to ensure plasmid maintenance. Cultures fermented at 37 °C and
280 rpm in 500 mL baffled shake flasks. Absorbance (OD600) of cultures were read at 1 in 12
dilution 2 or 3 times per hour for 12 hours. Simultaneously, fluorescence of 100 ul of cell culture
was measured in a Costar® 96-well black polystyrene plate (Corning Inc., Corning, NY) with
Synergy-MX Multi-Plate Reader (Biotek, Winooski, VT). ClearColiTM growth and induction
kinetics were assessed similarly with the following differences: overnight cultures of ClearColiTM
BL21(DE3) (Lucigen, Middleton, WI) and ClearColiTM BL21(DE3)-pY71-sfGFP were grown for
~18 hrs. OD600 and culture fluorescence were measured once per hour for 15 hours.

3.2.2

Extract Preparation with Autoinduction Media

Overnight cultures of E. coli BL21 StarTM(DE3) (~16 hrs) and ClearColiTM BL21(DE3)
(~18 hrs) were diluted 1/100 in duplicate 1.5 L auto-induction media ZYM-5052 prepared to 0.05%
final glucose concentration as described above in 2.5 L Tunair shake flasks (IBI Scientific, Peosta,
IA). Cultures were fermented at 37 °C and 280 rpm in between rapid cell harvests. Cell harvests
were performed at 6,000 g for 10 min, supernatant was discarded, and cells were immediately flash
23

frozen for storage at -80 °C. 700 mL, 450 mL, and 350 mL of BL21 StarTM(DE3) cell culture were
harvested at 4 hours (OD600 = 1.3), 5 hours (OD600 = 2.93), and 5.9 hours (OD600 = 5.0) of
fermentation, respectively. 700 mL, 300 mL, and 300 mL of ClearColiTM cell culture were
harvested at 5.4 hours (OD600 =1.0), 7.7 hours (OD600 = 3), and 9.8 hours (OD600 = 7.0) of
fermentation, respectively. About 0.3 gram cells were harvested per 100 mL culture per OD600.
Frozen cell paste was resuspended and washed (10 mL per gram cell) in sterile-filtered Buffer A
(10 mM Tris, 14 mM Magnesium Acetate, 60 mM, Potassium Glutamate, 1 mM DTT) and
centrifuged at 6,000 g for 10 min at 4 °C. Cells were once more resuspended (1 mL per gram cell)
in Buffer A before lysis with an Avestin EmulsiFlex-B15 homogenizer (Avestin, Ottawa, Canada),
3 passes at 20,000 psi. Cell lysate was centrifuged at 12,000 g for 10 min, and supernatant was
incubated at 37 °C for 30 min immediately prior to flash freezing and storage at -80 °C.

3.2.3

Cell-free Protein Synthesis Expression

CFPS reactions were formulated at 50 or 70 uL in 2 mL microcentrifuge tubes (BioExpress,
GeneMate). 25 volume percent cell extract was added to 12 nM plasmid DNA and the following
components: 10 to 20 mM magnesium glutamate (concentration optimized for protein yield), 1
mM 1,4-diaminobutane, 1.5 mM spermidine, 40 mM phosphoenolpyruvate (PEP), 10 mM
ammonium glutamate, 175 mM potassium glutamate, 2.7 mM potassium oxalate, 0.33 mM
nicotinamide adenine dinucleotide (NAD), 0.27 mM coenzyme A (CoA), 1.2 mM ATP, 0.86 mM
CTP, 0.86 mM GTP, 0.86 mM UTP, 0.17 mM folinic acid, and 2 mM of all the canonical amino
acids except glutamic acid, and incubated three hours at 37 °C and 120 rpm. Plasmid DNA (pY71)
containing the sfGFP gene under control of the T7 promoter was reported previously88. sfGFP
expression yields were determined by fluorescence at 485/510 excitation/emission wavelengths
according to a standard curve created by C14-leucine labeled proteins, as reported previously62. T7
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RNAP with an N-terminus hexa-histidine tag was expressed in BL21 StarTM(DE3) cells and
purified by HPLC with a His-TrapTM HP (GE Healthcare, Pittsburgh, PA). Crisantaspase was
expressed in 2 mL microcentrifuge tubes for 6.5 hrs at 30 °C and 120 RPM with amino acid
supplementation63, and yield was determined using C14 labeled leucine as previously described7.

Results and Discussion

3.3.1

Auto-induction Media for Cell-extract Preparation

This work combines - for the first time to our knowledge - the rapidly growing techniques
of cell-free protein synthesis and auto-induction media to create a streamlined method for
preparing the highly active cell extract necessary for CFPS. The purpose of fermenting E. coli cells
in auto-induction media is to eliminate the need for monitoring and manually inducing T7 RNAP
expression before harvest89, which requires 12 to 18 hours of hands-on time when preparing cell
lysate with the ClearColiTM strain7. Inducing expression of T7 RNAP during fermentation is
preferred because it achieves higher yields in CPFS than adding purified T7 RNAP89. In this work,
“yield” refers to the mass of protein produced per volume CFPS reaction. While several methods
for automatically inducing protein expression have been developed for a variety of applications9093

, this work utilizes auto-induction media with engineered concentrations of glucose and lactose,

as reported by Studier87. Briefly, autoinduction media operates on the principle of catabolite
repression of the lacUV5 promoter of the DE3 lysogen. When the preferred carbon source glucose
is present in culture media, cellular cyclic adenosine monophosphate (cAMP) levels remain low
and expression of the lacUV5-promoted protein (T7 RNAP in this work) is kept at a basal level.
As glucose is depleted, cellular cAMP levels rise, increasing transcription of the lacUV5 promoter
on DE3 lysogen if lactose is also present in the medium87,94. While the lacUV5 promoter is not
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repressed to the same degree as the wildtype lac promoter, experiments have shown that CAPactivated transcription from the lacUV5 promoter increases by more than two-fold in the presence
of cAMP95).

3.3.2

Autoinduction of BL21 StarTM(DE3) and ClearColiTM

To verify catabolite repression of the lacUV5 promoter, as well as to help determine the
optimal E. coli cell harvest time for CFPS extract production, we first assessed the kinetics of T7
RNAP autoinduction (specifically in the ZYM-5052 formulation87). This was performed by
fluorescence where a plasmid containing sfGFP under T7 RNAP promotion was transformed into
the cells. Both a BL21 StarTM(DE3) E. coli strain and an “endotoxin-free” BL21(DE3) E. coli
strain (ClearColiTM which is mutated to prevent the production of endotoxin60) were investigated.
Previously, both E. coli strains were reported to produce highly active extract for CFPS after shakeflask fermentation62,96. The results of these experiments suggest that induction of the DE3 lysogen
likely begins shortly after the onset of log growth phase for both BL21 StarTM(DE3) and
ClearColiTM (Figure 3-2). Importantly, these experiments indicate that cells fermented in otherwise
identical auto-induction media exhibit prolonged repression of the lacUV5 promoter in 1% glucose
when compared with 0.05% glucose.
Using this information, 0.05% glucose auto-induction media (ZYM-5025) was used to
ferment both BL21 StarTM(DE3) and ClearColiTM. Cells were harvested at early, mid, and later in
the log growth phase, then homogenized. Growth curves and harvest timepoints are shown in
Figure 3-2A. It is important to note that both E. coli strains did not contain the plasmid for sfGFP
production used in the above experiment. Extract for CFPS was prepared from the cell product by
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homogenizing, centrifuging, and incubating a “run-off” reaction to degrade preexisting mRNA as
detailed in the methods. The streamlined procedure of preparing extract using auto-induction

Figure 3-2: Study of BL21 StarTMDE3 and ClearColiTM growth and induction kinetics in ZYM-5052
auto-induction media containing 0.05% glucose or ZYM-512 media, which is modified to contain 1%
glucose. BL21 StarTMDE3 and ClearColiTM cells are WT or transformed with plasmid harboring T7
promoted sfGFP. Fluorescence of the culture (RFU) is measured directly in a black-well plate.
RFU/OD600 is a relative measure of sfGFP fluorescence per E. coli cell and is used to compare sfGFP
abundance between cultures of sfGFP-transformed cells grown in 0.05% glucose and 1% glucose. As
expected, induction of T7 RNAP expression is repressed in cultures grown in 1% glucose. Cultures
of cells grown in 0.05% glucose and harboring T7 promoted sfGFP begin to show increased
RFU/OD600 early in the logarithmic growth phase due to induction of T7 RNAP expression.
Accounting for the time required to transcribe and translate the sfGFP gene, these results suggest
that expression of T7 RNAP is induced near the onset of exponential growth in ZYM-5052 autoinduction media inoculated to 1/100 dilution. High initial RFU/OD600 in sfGFP-transformed cells is
likely because of leaky T7 RNAP expression during overnight growth. BL21 StarTMDE3 and
ClearColiTM cultures without plasmid harboring T7 promoted sfGFP serve as a negative control and
show no fluorescence for the duration of the fermentation. All cultures were inoculated with
overnight culture to 1/100 dilution. Error bars represent one standard deviation for n=2
fermentations.
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media relative to similar previously reported procedures is shown in Figure 3-1. The autoinduction-produced extract was then assessed for its ability to produce model protein sfGFP with
CFPS relative to extract prepared using the traditional method of OD600 monitoring, adding IPTG
at an OD600 of ~0.5 and then harvesting during log-phase. The results are shown in Figure 3-3B.

Figure 3-3: A. Growth curves (OD600) and harvest times of BL21 StarTM(DE3) and ClearColiTM E.
coli cells fermented in ZYM-5052 auto-induction media for CFPS cell extract preparation. Cells were
harvested at early, mid, and late logarithmic growth phase. Error bars on growth curves represent
one standard deviation for n=2 independent fermentations. B. Activity of BL21 StarTM(DE3) cell
extracts produced from early, mid, and late log-phase harvests. Cell extract activity is indicated by
expression yield of sfGFP in CFPS reactions. Error bars represent one standard deviation for n=4
CFPS reactions. Included for comparison is sfGFP expression yield from BL21 StarTM(DE3) cell
extract prepared from conventional monitoring and manual induction of T7 RNAP expression as
previously reported. C. Activity of ClearColiTM cell extracts produced from early, mid, and late logphase harvests. Error bars represent one standard deviation for n=4 CFPS reactions. Included for
comparison is sfGFP expression yield from ClearColiTM cell extract prepared using the traditional
method as reported by Wilding, et. al63.

3.3.3

BL21 StarTM(DE3) Cell Extract with Auto-induction

Cells harvested at mid and later into the log phase of BL21 StarTM(DE3) strain’s growth
(at 5 and ~6 hrs after inoculation) performed equivalently at producing protein in CFPS (Figure
3-2B). Alternatively, cells harvested early in the log-phase (4 hrs after induction) were ~50% less
productive (Figure 3-2B). Insufficient induction of T7 RNAP was hypothesized as the cause. This
is supported by additional experiments where adding purified T7 RNAP doubled the protein
producing capability of CFPS reactions using extract harvested at early log phase (Figure 3-4).
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Alternatively, adding T7 RNAP did not increase the yields when added to CFPS reactions from
mid to late-log phase (Figure 3-4). While the auto-induction method could alleviate the need to
continuously monitor OD600 to time manual IPTG induction, extract harvested from cells using the
traditional monitoring and manual induction method had the highest production capabilities
(Figure 3-3B).

Figure 3-4: Expression yield of sfGFP from BL21 StarTMDE3 and ClearColiTM cell extract made from
cells inoculated in ZYM-5052 auto-induction media to 1/100 dilution and harvested at early, mid, and
late logarithmic growth phase. CFPS reactions were formulated from each of n=2 fermentations with
the addition of purified T7 RNAP or storage buffer. Only BL21 StarTMDE3 cells harvested at earlylog growth phase show significant improvement in expression yield. These results suggest that CFPS
from the remaining cell harvests is not limited by T7 RNAP activity. Error bars represent one
standard deviation for n=2 CFPS reactions.

3.3.4

Endotoxin-free ClearColiTM Cell Extract with Autoinduction Media

In contrast to BL21 StarTM(DE3), CFPS extracts from auto-induced ClearColiTM achieved
similar cell-free yields from ClearColiTM extracts obtained using the traditional monitoring and
manual induction method (Figure 3-3C). This is particularly important as ClearColiTM has slower
growth kinetics and thus requires 12 to 18 hours of monitoring when preparing extract using the
traditional method. In addition, the window for harvesting is larger (between ~5.5 and 8 hrs after
induction for the early-log and mid-log harvest) (Figure 3-3, Figure 3-5) for obtaining high
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yielding extract which further simplifies using auto-induction media. Even waiting until 10 hrs
after induction produced decent protein expression yields. Although, at this time point the system
may be leaving log phase, which could be the reason for the ~20% drop in performance compared
to earlier harvested extract (Figure 3-3C). Together, these results demonstrate that preparing
ClearColiTM cell extract with auto-induction media produces equivalent-yielding CFPS but is up
to 20% faster and simpler than traditional monitoring and induction. We therefore recommend
auto-induction fermentation whenever cell extract is prepared with ClearColiTM.

Figure 3-5: Growth curve of ClearColiTM cells inoculated with overnight culture to 1/100 dilution in
ZYM-5052 auto-induction media. Error bars represent one standard deviation for n=2 fermentations.

3.3.5

Endotoxin-free Production of Crisantaspase

In a previous study, we discovered that residual endotoxin in our BL21*(DE3) cell extract
registered limulus amebocyte lysate (LAL) reactivity of ~2x107 EU/mL7. This is not altogether
surprising because lipopolysaccharide (LPS) is found in the outer membrane of gram-negative
bacteria, and previous reports affirm that E. coli cell membrane is not fully removed during lysate
clarification98. In contrast, ClearColiTM cells incorporate a chemically distinct LPS into their outer
membrane which is not capable of eliciting a human immune response60,61. To demonstrate protein
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therapeutic production with inherently endotoxin-free auto-induced ClearColiTM cell lysate,
extract from the early harvest (~5.5 hrs after induction) was used to synthesize Acute
Lymphoblastic Leukemia therapeutic crisantaspase to a final concentration of 280 ng/uL (Figure
3-6). The crisantaspase is a tag-less biosimilar to the FDA-approved drug currently on market.
Importantly, this yield is similar to yields of crisantaspase from traditionally prepared BL21
StarTM(DE3) extract (Figure 3-6).

Figure 3-6: Soluble protein expression yield of biosimilar to FDA-approved cancer therapeutic
crisantaspase using ClearColiTM cell extract prepared with autoinduction media and harvested at
early-log phase. For comparison, soluble expression of crisantaspase obtained with BL21 StarTM(DE3)
cell extract prepared using the traditional method is provided. This reference is the highest reported
CFPS yield of tag-less crisantaspase previously reported in literature.

Conclusion
Auto-induction media is a productive strategy for preparing cell extract for E. coli-based
CFPS. The use of auto-induction as presented can significantly reduce the amount of hands-on
time required for preparation of cell extract and eliminate the need for manual induction.
Previously, optical density had to be continuously measured and the culture manually induced at
precisely the correct time. Auto-induction, however, reduces the monitoring needed and offers
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significant potential for standardizing cell extract preparation. This technique is particularly
relevant to extract prepared from the slow-growing “endotoxin-free” ClearColiTM cells, where the
larger range of possible harvest times enables overnight culturing. Additionally, the auto-induced
endotoxin-free extracts produce protein at similar levels to traditionally prepared endotoxin-free
extracts and were used to produce the therapeutic protein crisantaspase at high titers. Streamlined
preparation of endotoxin-free cell extract improves accessibility to on-demand expression
technologies toward alleviating drug shortages and expanding global access to life-saving
therapeutics.
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4

ENHANCED CELL-FREE OXYGEN TRANSPORT THROUGH HYDROFOAM
AND OXYGEN HEADSPACE BIOREACTORS

This chapter is an adaptation from the article by J. Andrew D. Nelson, R. Jordan Barnett,
J. Porter Hunt, Isaac Foutz, Meagan Whelton, and Bradley C. Bundy entitled, “Hydrofoam and
oxygen headspace bioreactors improve cell-free therapeutic protein production yields through
enhanced oxygen transport,” published by Biotechnology Progress September 2020,
https://doi.org/10.1002/btpr.3079.
JPH conceived this study after noting the effect of inadvertent bubbles on cell-free protein
synthesis yield. JPH also performed the simulations, participated in laboratory experiments, and
contributed significantly to writing, revising, and responding to reviewers’ comments. JPH is
grateful to J. Andrew D. Nelson, R. Jordan Barnett, Isaac Foutz, and Meagan Whelton for
experimental work, and especially to J. Andrew D. Nelson for being the driving force behind
completing the study. JPH is also grateful to Professor Andrew Fry for oxygen equipment and
safety consultation, and to Professor David Lignell for numerical methods consultation.

Introduction
In 1982, the Food and Drug Administration approved Humulin (rh insulin) as the first
recombinant protein for human therapeutic use99. Since then, protein-based therapeutics have
become an increasingly important division of biopharmaceutical production. Recent years have
seen the number of approved protein-based biopharmaceuticals soar to nearly 400100. In 2018,
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recombinant proteins accounted for 87% of all newly approved biopharmaceuticals and topped
small molecules for the first time when considering the top 100 pharmaceuticals by world-wide
sales101.
Due to its fast growth, simple culturing procedure, and cost-effectiveness, E. coli is still
commonly used to synthesize protein therapeutics which treat diabetes, cancer, growth disorders,
and many other debilitating diseases102. However, bioreactors designed to produce these important
proteins are commonly oxygen-limited, even featuring localized zones of oxygen depletion103-106.
Foam formation has been shown to increase oxygen transfer107 but is often avoided in bioreactors
due to its tendency to damage cells108,

109

. Because of this, bioreactors commonly employ

antifoams110.
In addition to oxygen transport limitations, cost, storage, and transportability remain large
obstacles to the administering of biologic therapeutics throughout the world, especially in lowand middle-income countries. A particularly disheartening example is seen in cancer, where 5
million of the 7 million annual deaths across the world occur in low- to middle-income countries111.
While treatments for these debilitating diseases exist, a large number of cases go untreated due to
the inability of those in low- to middle-income countries to afford, store, and transport these
therapeutics.
Magistral or point-of-care therapeutic protein production has gained interest in recent years
as a means of overcoming these and other obstacles112-114, and cell-free protein synthesis (CFPS)
has emerged as an especially promising platform for magistral biologic production. In particular,
recent breakthroughs have shown that shelf-stable, lyophilized, cell-free reagents maintain their
viability over extended periods of time, even up to 60 days after aqueous extracts succumb to
temperature or bacterial degradation115. These systems have been further engineered to produce
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highly active, FDA-approved therapeutics in a single-batch, “just-add-water” and DNA system116.
Furthermore, CFPS has demonstrated utility in other therapeutic applications, including
optimization of PEGylation (commonly used for 2nd generation protein therapeutics)117,
biosensing118, 119, production of viruses and virus-like particles for therapeutic use120, and genecircuits121, 122, to name a few.
Despite the promising potential of CFPS, prior research has shown that, like their cellbased counterparts, batch cell-free reactors are also oxygen-limited123, 124. It has been hypothesized
that inverted membrane vesicles (IMVs) facilitate ATP regeneration through oxidative
phosphorylation in E. coli CFPS125, 126, and these oxygen transport limitations have previously
been ameliorated with thin film and bubble column reaction formats127. More recent work has led
to the development of continuous-flow, tube-in-tube CFPS reactors which facilitate oxygen
diffusion128. Because CFPS is not subject to the constraint of maintaining cell viability, we
hypothesized that CFPS can harness the ability of foam to increase oxygen transport and thus
protein yields without the negative effects seen in cell-based reactors.
To improve CFPS technology and help address the ever-growing demand for protein
therapeutics, we report a novel hydrofoam reactor design with the potential to improve therapeutic
production yields from an E. coli-based cell-free protein synthesis (CFPS) system. We further
show that replacing the reaction headspace with oxygen gas increases yields, but not as effectively
as hydrofoam. We demonstrate the impact of these reaction formats by producing an FDAapproved cancer therapeutic that is commonly out-of-stock due to manufacturing issues. This,
combined with other previously developed lyophilization technologies, is opening the door for
low-cost, transportable, magistral medicine to become a reality, with the potential to increase
protein therapeutic availability throughout the world.
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Materials and Methods

4.2.1

Extract Preparation and CFPS

BL21 StarTM (DE3) cell extract was prepared as previously described129. Extract was then
flash frozen in liquid nitrogen and stored at -80°C until use. CFPS reactions were prepared as
previously described130. In brief, reactions were prepared in 1.5 mL Eppendorf tubes with 25% v/v
cell extract, 12 nM pY71-sfGFP, optimized concentrations of magnesium glutamate (10 – 20 mM),
1 mM 1,4-diaminobutane, 1.5 mM spermidine, 40 mM phosphoenolpyruvate (PEP), 10 mM
ammonium glutamate, 175 mM potassium glutamate, 2.7 mM potassium oxalate, 0.33 mM
nicotinamide adenine dinucleotide (NAD), 0.27 mM coenzyme A (CoA), 1.2 mM ATP, 0.86 mM
CTP, 0.86 mM GTP, 0.86 mM UTP, 0.17 mM folinic acid, and 2 mM of the 20 natural amino
acids. Reactions were incubated at 37°C for three hours without shaking.

4.2.2

Creating CFPS Hydrofoam

CFPS air reactions were performed with and without foam at 30, 50, 70, and 90 μL liquid
volumes. Foam was created by pipetting repeatedly with a 200 uL pipet tip into the liquid until the
liquid was completely foamed. Foaming completion was assessed by achieving a 10 fold increase
in volume occupied by the CFPS liquid. CFPS nitrogen reactions were performed by blowing
nitrogen gas (>99.5 % nitrogen, Airgas) over the CFPS liquid for two minutes to displace the air
from tubes. Tubes were then quickly capped. CFPS yields in the presence of the nitrogen gas
headspace were tested at 30, 50, 70, and 90 μL. CFPS oxygen reactions were performed identically
to the CFPS nitrogen reactions, but using pure oxygen gas (>99.5% oxygen, Airgas) rather than
nitrogen gas.

36

4.2.3

Quantifying Protein Expression

Protein yields were determined using

14

C-leucine scintillation counting as previously

described130. 14C-leucine was added to each cell-free reaction at a concentration of 5.25 μM. After
the addition of radioactivity, reactions were similarly repeatedly pipetted with a 200 μL pipet ~20
times to generate a foam with ~10-fold increase in volume compared to the original CFPS liquid
volume. At the reaction’s finish, each sample was spun at 13000 RPM to clear any remaining foam
for easier pipetting. Thus, all protein yields reported represent soluble yields. A Beckman LS3801
Liquid Scintillation Counter and EcoLumeTM Liquid Scintillation Cocktail were then used to
measure sample radiation. Wash samples were washed in 5% TCA three times for 15 minutes.
Amount of synthesized protein was then determined based on the percent of

14

C-leucine

incorporated into the protein. Asparaginase-producing CFPS reactions and activity assays were
performed as previously reported119.

4.2.4

Simulations

Oxygen diffusion and consumption in CFPS was modeled by applying a one-dimensional
continuity equation to oxygen in both transient and steady state forms to a CFPS liquid with
homogeneous oxygen consumption described by Michaelis-Menten kinetics (See Figure 4-1A).
Simulations are detailed in “Results and Discussion”.

Results and Discussion

4.3.1

Simulating Oxygen Consumption in Cell-free Protein Synthesis

Oxygen diffusion and consumption in CFPS was simulated by applying a one-dimensional
continuity equation for O2 in a CFPS liquid with homogeneous Michaelis-Menten O2 consumption
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kinetics (Figure 4-1A), where [O2] is the liquid concentration of O2, vmax is the Michaelis-Menten
maximum catalytic velocity, Km is the Michaelis-Menten constant for enzymatic O2 consumption,
and DO2 is the diffusivity of O2 in serum1. Simulated dimensions of a 1.5 mL microcentrifuge tube
and subsequent CFPS liquid levels are shown in Figure 4-2.

Figure 4-1: Steady-state oxygen transfer and consumption simulation results. A. The steady-state
continuity equation with Michaelis-Menten consumption. Vmax was obtained by fitting simulated
oxygen flux through the gas-liquid interface to experimental CFPS O2 consumption estimates. Km
was estimated based on literature values131 and the solubility of oxygen132. The diffusivity of O2 in
CFPS was estimated as the diffusivity of O2 in plasma133. B. Representation of simulated steady-state
O2 concentration in tube-batch CFPS reactions of increasing volume. Reactions under O2 and air
headspace are represented, along with O2 concentration in CFPS hydrofoam film. *As shown in
Figure 4-5, foaming significantly increases tube volume occupied by the CFPS reaction. C. Simulated
CPFS yield using foam, pure O2, control air, and pure N2, assuming 35% ATP required for protein
translation derived from oxygen-dependent pathways in pure O2 reactions.
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Figure 4-2: A. Cross-sectional dimensions of simulated CFPS liquid in microcentrifuge tube for
oxygen, air, and nitrogen headspace simulations. For CFPS volume and flux calculations, the
stationary liquid occupying the tube was modeled as a cone with a spherical cap of radius 2.8 mm. B.
“Hydrofoam” simulation from spheres of radius 1.5 µm and liquid shells of film thickness 50 nm. All
hydrofoam CFPS liquid was assumed to comprise one thin film with mass transfer surface area (Asurf)
estimated as the sum of the surface areas of all spheres, where n is the number of spheres determined
from the volume of CFPS and r is the sphere radius.
v

The boundary conditions at the tube wall and gas-liquid interface · are the zero-flux conditions
and gas-phase equilibrium, respectively, and are shown below with Equation 4-1 and Equation 42, where [O2] is the liquid concentration of O2, Hserum is the Henry’s law constant for O2 in serum,
and pO2 is the gas-phase O2 pressure.
d[O2 ]
dx

�

tube wall

=0

(4-1)
(4-2)

[O2 ]surface = Hserum ∙ pO2

CFPS liquid O2 concentrations in equilibrium with the gas phase were estimated using the
Henry’s law constant for partial pressure of O2 (pO2) in serum at 37 ºC: 0.0214 mL O2/atm O2/mL
serum132. Atmospheric O2 partial pressure in Provo, Utah, USA was calculated at 0.178 atm. Pure
O2 pressure dispensed to 0 psig in Provo, Utah, USA was calculated at 0.849 atm. The initial O2
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concentration in CFPS was taken as the saturating concentration of O2 in serum in the presence of
Provo air. The Michaelis-Menten constant (Km) for the system was estimated at 10 µM based on
the solubility of O2 in serum and supported by literature values for cytochrome c oxidase131.
Volumetric O2 consumption by CFPS was estimated using the following assumptions: 4.2 mol of
ATP are required for aminoacylation and polymerization of one mol amino acid residues, and 1
mol ATP is generated from each mol O2 consumed134. When CFPS is not oxygen-limited, protein
synthesis rate averages 0.4 mg/mL/hr over a three-hour reaction (Figure 4-1, 30 µL reactions).
Observing that the experimental difference in CFPS yield between N2 and O2 headspace at 30 µL
reaction volume is between 35% - 55% (Figure 4-1), we conservatively estimated that 35% of
protein yield from oxygen-headspace CFPS is attributed to oxygen-dependent metabolic pathways.
Under steady-state conditions, O2 flux through the CFPS liquid surface is equivalent to the
consumption of O2 in CFPS, and Fick’s first law was used to calculate O2 flux into the CFPS liquid
from the headspace. Equating the consumption of O2 in CFPS with the flux of O2 into the CFPS
liquid yields Equation 4-3, where [O2] is the liquid concentration of O2, DO2 is the diffusivity of
O2 in serum133, Asurf is the surface area of the reaction’s gas-liquid interface, Vrxn is the CFPS liquid
volume, and CFPS O2cons is the volumetric consumption of O2 in oxygen-headspace CFPS
estimated from experimental data (Figure 4-1) as described.
DO2 ∙Asurf d[O2 ]
�
dx surface
Vrxn

= CFPS O2 cons

(4-3)

This equation was applied to the 30 µL reaction simulation with O2 headspace to obtain an
estimate of vmax. The resulting parameter estimate of vmax is included in Figure 4-1, and was used
to simulate the protein yield of CFPS reactions under oxygen headspace at 50 µL, 70 µL, and 90
µL reaction volumes, under air headspace at 30 µL, 50 µL, 70 µL, 90 µL reaction volumes, and in
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hydrofoam at 30 µL, 50 µL, 70 µL, and 90 µL reacting liquid volumes.
Hydrofoam was modeled as close-packed spherical bubbles with radius 1.5 µm and a
conservative film thickness of 50 nm. The aggregate bubble surface area was used to calculate O2
flux into the CFPS liquid. The simulated CFPS hydrofoam film was not O2 mass-transfer limited
and maintained essentially saturated steady-state O2 concentrations throughout the liquid (Figure
4-3).

Figure 4-3: Simulated steady-state O2 concentration under both air and pure oxygen head gas.
Simulated liquid film thickness is also represented.

After the continuity equation was solved for each reaction condition and geometry, the
corresponding O2 flux into the CFPS liquid was converted into protein yield using the above
assumptions and added to the baseline anaerobic CFPS yield of 65% of total yield from 30 µL
oxygen headspace reactions. The resulting predicted protein yields are reported in Figure 4-1.
In order to quantify the potential effect of the transient regime on CFPS O2 consumption,
simulations were also performed with the transient continuity equation for O2 in CFPS, Equation
4-4, with analogous boundary conditions to the steady-state simulation shown with Equation 4-5
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and Equation 4-6, where [O2] is the liquid concentration of O2, DO2 is the diffusivity of O2 in
serum133, Hserum is the Henry’s law constant for O2 in serum, vmax is the Michaelis-Menten
maximum catalytic velocity, Km is the Michaelis-Menten constant for enzymatic O2 consumption,
and pO2 is the gas-phase O2 pressure.
∂[O2 ]
∂t

∂[O2 ]
∂x

= DO2
�

∂2 [O2 ]

tube wall

∂x2

− vmax �

[O2 ]

Km +[O2 ]

(4-4)

�

(4-5)

=0

(4-6)

[O2 ]surface = Hserum ∙ pO2

Based on the assumptions described above and a total tube volume of 1.5 mL, CFPS consumes
about 1% and 4% of total O2 in the headspace for pure O2 and air headspace reactions, respectively.
The transient headspace O2 concentration was represented accordingly, and the transient equation
was solved with finite differences on finite elements. vmax was estimated by equating the total
oxygen consumption in the 30 µL oxygen headspace CFPS reaction with the sum of O2
consumption in each finite element summed over all finite differences, as shown in Equation 4-7,
where [O2] is the liquid concentration of O2, vmax is the Michaelis-Menten maximum catalytic
velocity, Km is the Michaelis-Menten constant for enzymatic O2 consumption, and pO2 is the gasphase O2 pressure, Atube is the cross-sectional area of liquid CFPS at each finite element, and CFPS
O2cons is the volumetric consumption of O2 in oxygen-headspace CFPS estimated from
experimental data as previously described.
CFPS O2 cons = ∑ni=0 ∑tj=0 vmax �K

[O2 ]i,j

m +[O2 ]i,j

� ∆xi ∙ Atube i ∙ ∆t j

(4-7)

The estimated vmax obtained by this method was 2 µM/s, in excellent agreement with the steadystate parameter estimate (Figure 4-1). Transient simulations reach a steady O2 concentration within
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~2 mins (Figure 4-4) and the simulated transient O2 consumption over 180-minute reaction time
agrees with that of the steady state simulation to within ~12%. Thus, the steady-state simulation
adequately represents O2 concentration in the CFPS liquid under the assumptions used for these
simulations, and illustrates the significant advantage of hydrofoam in overcoming O2 transport
limitations in CFPS.

Figure 4-4: Transient simulation of O2 consumption in CFPS after the indicated reaction duration
representing A. air and B. O2 headspace.

Even after applying conservative oxygen consumption assumptions, these simulations
demonstrated decreased dissolved oxygen concentrations with larger volume reactions (Figure
4-1). As expected, simulation results also indicated that replacing the headspace air with pure
oxygen improves oxygen transfer and availability in the CFPS liquid (Figure 4-1). However, even
these reactions appeared to be oxygen-limited. We hypothesized that the creation of a “hydrofoam”
would greatly increase the surface area to volume ratio of the CFPS liquid and overcome oxygen
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transport limitations. Simulations of oxygen transport across the thin foam “bubble” walls support
this hypothesis (Figure 4-1).

4.3.2

Air, Hydrofoam, and Oxygen Reactions

The simulated conditions were experimentally verified with GFP-producing E. coli-based
CFPS reactions performed for 3 hours at 37oC with 30, 50, 70, and 90 μL volumes with the
following conditions: air headspace, oxygen headspace, nitrogen headspace, and a “hydrofoam”
created with air. A picture of a “hydrofoam” batch reaction is shown in Figure 4-5A, and the raw
data is plotted in Figure 4-5B. These results are consistent with simulation results. As shown by
a linear regression of the data in Figure 4-5C, the “hydrofoam” format achieved consistently higher
protein production yields, which remained fairly consistent with increasing liquid volumes. In
contrast, the traditional air-headspace batch reactions dropped in yield by up to 30% as the reaction
volume increased. At reaction volumes of 50 μL and greater, the “hydrofoam” format
outperformed the traditional air headspace reactions by 40 to 100%. This simple technique
introduces minimal error, as evidenced by the small error bars (Figure 4-5). To ensure
reproducibility, the reaction volumes occupied by the hydrofoam were visually confirmed to
achieve a ~10-fold increase over the initial CFPS liquid volume (Figure 4-6).
Adding pure oxygen to the headspace significantly improved reaction yields and is a viable
means of improving batch CFPS yields. It should be noted that, as shown by the linear regression
in Figure 4-5D, the yields dropped at higher volumes suggesting that the reaction format remains
oxygen-limited at higher reaction volumes. To further verify oxygen limitation, the oxygen in the
headspace was replaced by nitrogen gas. This resulted in the lowest production rates, which
remained relatively constant with increasing reaction volume (Figure 4-5D). This suggests that the
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difference in protein yield between the nitrogen and the oxygen environments is a result of oxygen
diffusing from the gas phase to the liquid phase. Pure nitrogen was chosen, as the traditional air

Figure 4-5: A. Image of hydrofoam reaction created by foaming CFPS reactants with air. B. Cell-free
GFP yields at 30, 50, 70, and 90 μL. Reactions were conducted in the presence of hydrofoam (foam),
pure O2 in the headspace, non-foamed air in the headspace (control air), or pure N2 in the headspace
to show the maximum CPFS possible without O2. Yields were determined by radiolabeling with 14Cleucine. C. Linear fit of GFP yield vs. reaction volume for foamed and non-foamed reactions. Data
points represent mean of n=2 cell-free reactions. Shaded areas represent 95% confidence intervals.
D. Linear fit of GFP yield vs. reaction volume for pure O2 and pure N2 reactions. Points represent
mean of n=2 cell-free reactions. Shaded area represents 95% confidence intervals.

headspace reactions contain ~79% nitrogen in the headspace and increasing nitrogen content is not
expected to have adverse effects beyond removing oxygen.
Similar to the work from the Swartz lab where thin film batch reaction formats improve
CFPS yields likely due to improved oxygen transfer124, recent work by Lin et al. utilized a complex
tube-in-tube reactor design to achieve very short ~0.3 mm oxygen diffusion lengths and thus
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achieved saturating oxygen conditions in reacting E. coli CFPS liquid135. By comparison,
hydrofoam reactors provide a simpler format to minimize oxygen diffusion lengths and achieve
enhanced oxygen transport in a simple batch reaction format which will likely translate into greater
utility and flexibility for point-of-care therapeutic production as the field advances.
For simplicity, the “hydrofoam” was created only at the start of each batch reaction. This
approach is supported by prior publications from multiple labs that report most of the product
protein is produced and highest protein production rates are achieved in the first 0.5 to 1 hr136, 137.
Thus, the reaction is likely to have the greatest energy limitation at the start. A time-lapse of foam
volume content is shown in Figure 4-6 for both the 30 and 90 uL liquid volume reaction formats.
The majority of the foam content remains over the first 1.5 hours. Manually refoaming the reaction
over the course of the reaction may further increase yields, however, the fairly consistent
production yields with increasing reaction volumes obtained by the “hydrofoam” reaction format
suggest that oxygen is not limiting. For larger volume reactions, refoaming may be necessary for
optimal production yields.

Figure 4-6: A. Time-lapse of 30 μL hydrofoamed GFP-producing cell-free reaction at 0, 30, 60, 90,
and 205 minutes. Foam volume percent decrease over time is also noted. B. Time-lapse of 90 μL
foamed GFP-producing cell-free reactions at same time intervals.
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While it is clear from these data that foam increases CFPS yields primarily through
increased oxygen transport, the curvature of bubbles has also been shown to cause shear stresses
which can improve catalysis kinetics138,

139

. Thus, while the nitrogen-headspace and oxygen-

headspace controls are suggestive, we cannot completely rule out some amplification due to the
bubble format itself.
Though some reports state that oxidative phosphorylation is not active in CFPS from E.
coli S30 extract123, 140, literature provides convincing evidence that CFPS from clarified E. coli
lysate is oxygen limited124, corroborating the results of this study. Future work is needed to uncover
the oxygen-dependent molecular mechanisms associated with increases in CFPS production yield
and assess the extent to which oxidative phosphorylation may participate.
While GFP yield was reported and visualized, it is important to emphasize the resultant
yields were determined by radiolabeling and scintillation counting rather than GFP fluorescence
levels. Due to differing oxygen content and the requirement of oxygen for GFP maturation, there
was concern that differences in GFP maturation rates could incorrectly be interpreted as improved
expression yields if fluorescent levels were measured.
It should be noted that due to cell-lysis when foam bubbles coalesce, CFPS is much more
amenable to a foam-based reaction than are cells. However, prior studies have also suggested that
protein stability and protein folding can be negatively affected by shear stresses in the film of a
bubble141, 142. Impressively, though, the proteins involved in transcription and translation (T7 RNA
polymerase, ribosomes, initiation factors, elongation factors, release factors, tRNA synthetases,
etc.) do not appear to be negatively impacted, as the foam-based format resulted in higher protein
expression. GFP folding was not hindered, as its activity did not decrease in the foam format.
However, the GFP version used herein is a super-folder version with faster folding and higher
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stability than many proteins. In addition, the proteins involved in transcription and translation are
already folded before the reaction commences, while shear stress effects are anticipated to have
the greatest influence on proteins as they fold into their correct state

4.3.3

Crisantaspase Production with Air, Hydrofoam, and Oxygen

To further verify that the shear-strain effect would not hinder the foam format, we used
this format to express an FDA-approved therapeutic, L-asparaginase from Erwinia chrysanthemi,
crisantaspase (Erwinaze), which is used to treat acute lymphoblastic leukemia (the most common
form of childhood cancer). This therapeutic is difficult to produce and production difficulties by
the world’s only provider (Jazz Pharmaceuticals) commonly result in the product being out-ofstock for months according to FDA-listed shortages119. As shown in Figure 4-7A, the specific
activity of Erwinaze produced using the 70 μL foam-based CFPS format was ~40% lower than the
control reactions with air or oxygen in the headspace. Researchers should be aware of this, as
dosages containing inactive product protein have the possibility of adverse effects. The observed
decrease in activity is potentially a result of foam interfering with protein folding as more proteins
are exposed to the shear stresses associated with surface tension. However, it was produced at
almost 3 times the yield as the air control, which resulted in higher absolute activity than the air
control (Figure 4-7B). Similar to the GFP results, adding oxygen to the headspace also improved
production yields, albeit not to the same extent as foam. Oxygen-headspace reactions maintained
a similar level of specific activity to the air control, thus leading to the highest absolute activity
(Figure 4-7B).
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Figure 4-7: A. Bars represent the production yields of Erwinaze from 70 μL cell-free reactions using
the hydrofoam format, pure O2 headspace format, or air headspace format. Error bars represent
the standard error for n=2 reactions. Between hydrofoam and pure O2 headspace reactions,
p=0.0078; hydrofoam and air headspace, p=0.0030; pure O2 and air headspace, p=0.0095. The “x”
data points represent the specific activity of Erwinaze produced from each respective reaction format.
Error bars represent the 90% confidence interval for n>2 activity assays. B. Absolute activity of
Erwinaze from 70 μL cell-free reactions using the reaction formats from part A with error bars
representing the 90% confidence interval for n>2 activity assays.

The active form of Erwinaze is a tetramer, perhaps contributing to its difference from GFP
in ability to fold correctly under the hydrofoam format. While some therapeutic proteins’ folding
may be impacted with this format, stable, self-folding, monomeric proteins such as GFP appear to
be amenable to foam-based production.
While the laboratory volumes tested here are below those necessary to supply an effective
dose of Erwinaze, both the foam-based and oxygen-headspace formats are valuable contributions
towards the development of dosage-scale point-of-care therapeutic production. Large-scale
incorporation of hydrofoam could be achieved continuously by foaming nozzles similar in design
to those used to dispense hand soap. Advances which improve CFPS production of therapeutics
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such as the presented work are especially critical as they reduce the reactor size that would be
necessary for magistral manufacturing. Oxygen is readily available in clinical settings throughout
the world and can be easily accessed for therapeutic production purposes on-demand. Care should
be taken when handling pure oxygen. Oxygen headspace reactions had no reduction in specific
activity and increased therapeutic yields by over 80%. In remote areas of the world where this is
not feasible, our foam-based format – which expressed Erwinaze with a total activity 50% greater
than the air control – can similarly be used to increase yields and drive down cost.

Conclusion
Overall, in this work, we have demonstrated the utility of a very simple technique to
increase yields in CFPS reactions. By taking a few seconds to simply pipet air throughout the
reaction volume, yields were shown to increase by 40 to 100% in “larger” microliter volume
reactions with sustained higher yields over increasing volumes. In addition, the impact of oxygen
transport was modeled and matched experimental results. The simulation results suggest that
oxygen consumption is an important consideration when mathematically modeling CFPS
performance, and when engineering the metabolism of E. coli CFPS. Finally, as computationally
predicted, the hydrofoam format in CFPS reactions improved the yield and absolute activity of an
FDA-approved cancer therapeutic.
There is some concern that the foam-based format may not be suitable for certain protein
products due to possible bubble-induced surface tension inhibiting protein folding. Thus, we also
demonstrated that simply adding oxygen to the headspace can also increase protein yields and
mitigate some of the oxygen transfer limitations at larger reaction volumes. This is a particularly
attractive option for point-of-care production of protein therapeutics at hospitals, as oxygen is
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commonly available. Only a few mL of oxygen at standard temperature and pressure is needed. If
oxygen is not available in a remote area of the world, foam is an effective alternative for many
therapeutics like Erwinaze. Thus, in conjunction with recent cell-free advances which increase
stability and transportability of reagents, this new hydrofoam format provides promise for a future
of point-of-care, magistral production and administration of protein therapeutics at an affordable
cost throughout the world.
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5

DEVELOPING A CELL-FREE BIOSENSOR OF ESTROGENIC MOLECULES

This chapter is an adaptation from the article by Amin S.M. Salehi, Seung Ook Yang,
Conner C. Earl, Miriam J. Shakalli Tang, J. Porter Hunt, Mark T. Smith, David W. Wood, Bradley
C. Bundy entitled, “Biosensing estrogenic endocrine disruptors in human blood and urine: A
RAPID cell-free protein synthesis approach,” published in Toxicology and Applied Pharmacology,
15 April 2018, Volume 345, Pages 19-25, https://doi.org/10.1016/j.taap.2018.02.016.
The contribution of JPH to this work was primarily writing and revising the manuscript,
responding to reviewers, and experimentally assessing the impact of thyroid hormones on the
estrogen sensor. The entire work is presented in this dissertation to provide context for the
contributions of JPH, who is grateful to Amin S.M. Salehia, Seung Ook Yang, Conner C. Earl,
Miriam J. Shakalli Tang, Mark T. Smith, and our collaborator David W. Wood for the opportunity
to contribute to this work!

Introduction
Unintentional as well as intentional discharge of harmful chemicals into the environment
has been the conventional reality of industrialized society for hundreds of years. In recent decades,
an increasing wealth of evidence has shown a certain class of chemicals known as Endocrine
Disrupting Chemicals (EDCs) to be of concern143. Studies have detected significant levels of EDC
activity in air144, soil145, drinking water146, food147, personal care products148, pharmaceuticals149,
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and synthetic hormones149. These studies suggest that EDC exposure likely contributes to acute
and chronic conditions including cancer150, diabetes151, obesity148,152, metabolic syndrome153,
infertility148, and permanent brain damage148. A recent report estimated an EDC-exposure health
burden of $340 billion USD in the United States and $209 billion USD in the EU151.
One class of EDC’s known as xenoestrogens (XEs) interferes specifically with the function
of estrogen receptors. XEs originate from both natural (e.g. soy plants) and unnatural (e.g. BPA)
sources. Research has linked exposure to XEs with obesity154, birth defects155 including DNA
methylation and placental alteration156, cancer157, reproductive impairment158, cognitive
disabilities159,160, and developmental disorders161. Thus, public chemical safety would be enhanced
with rapid, reliable, and cost-effective methods to screen chemicals, environmental samples, and
human/animal samples for high levels of XE activity.
Characterizing XE interactions with estrogen receptors also benefits medical technology.
Pharmaceuticals called selective estrogen receptor modulators are currently used to treat a variety
of conditions including infertility, breast cancer, and postmenopausal complications, and are one
of the World Health Organization’s “essential medicines”162,163. Rapid screening technologies for
ER modulators are valuable tools in drug discovery and characterization. Detection of estrogens
and their derivatives in blood and urine samples is also an important diagnostic tool164,165.
Long-standing methods for detecting XEs utilize yeast and human cell lines166-172. While
these are reliable and sensitive, their complicated laboratory procedures and long assay durations
prohibit rapid screening and in-field detection149,173,174. LC/MS and GC/MS are likewise popular
techniques, but require trained technicians and significant equipment (~$190,000)174-177. Strategies
employing biosensor proteins have been investigated in whole-cell178 and purified-protein
formats179, but these methods require mammalian cell culturing and protein purification, both of
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which are cumbersome processes. There is a need for rapid and inexpensive methods for
identifying XEs.
In a recent study, we introduced our Rapid Adaptable Portable In-vitro Detection biosensor
platform (RAPID) for determining EDC activity180. This biosensor platform relies on exploiting
the basic cellular mechanism of EDC activity in the following manner. an allosterically activated
fusion protein containing the ligand-binding domain of a nuclear hormone receptor (NHR) and the
reporter enzyme β-lactamase is synthesized in a cell-free protein synthesis (CFPS) reaction in the
presence of a sample. If the sample contains NHR binding ligands, an increase in colorimetric
signal is generated real-time. Unlike many emerging biosensor technologies, the RAPID biosensor
is not analyte specific. Instead, the sensor detects binding interactions with a NHR.

Figure 5-1: Scheme of RAPID biosensor assay and its mechanism of action. A) Estrogen receptor β
RAPID biosensor construct. The conformation of the human estrogen receptor β changes upon
interaction with hERβ-specific ligands. The conformation change transfers through the intein
domain to and the reporter enzyme (β-lactamase) which then becomes activated. B) The RAPID
biosensor assay. The biosensor assay can be performed in the presence of human bodily samples
(urine and blood). The presence of estrogen hERβ-specific ligands in the sample triggers a color
change in the assay, which can be observed visually or more accurately measured using a
spectrometer.
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Our previous work demonstrated the utility of this biosensor to detect and screen EDCs that
interact with the Human thyroid receptor β (hTRβ). In this work, we demonstrate the modular
nature of the RAPID biosensor by replacing the hTRβ domain with that of the human estrogen
receptor β (hERβ) to detect XEs. The CFPS reaction allows direct utilization of the biosensor
protein without cell culture or protein purification. We further engineer the CFPS biosensing
reaction using RNAse inhibitors to achieve significantly enhanced protein synthesis, and thereafter
XE detection, in human blood and urine. To our knowledge, this is the first report of biosensor
proteins produced in CFPS reactions engineered to overcome adverse sample matrix effects.

Materials and Methods
All EDC ligands were purchased from Sigma-Aldrich (St. Louis, Missouri USA):
diarylpropionitrile (DPN), bisphenol A (BPA), β-estradiol (E2), and TRIAC (3,3′,5triiodothyroacetic acid). Blood samples were purchased from Innovative Research (Novi,
Michigan, USA). The human donor urine was donated anonymously by the BYU health center.
Nitrocefin was purchased from Cayman Chemical (Ann Arbor, Michigan USA), and murine
RNAse inhibitor was purchased from New England Biolabs (Ipswich, Massachusetts).

5.2.1

Biosensor Design and Construction

The pDB-MI-hERβ-β-lac construct was created in a similar manner as our previous
biosensor construct38. The pDB vector encodes for the biosensor protein complex that comprises
four domains: maltose binding domain (MBD), human estrogen receptor β (hERβ), β-lactamase,
and two split intein segments between MBD and hERβ, and hERβ and β-lactamase. The gene
encoding this protein is under control of the T7 promoter. The construction of the vector was
detailed previously38.
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5.2.2

Cell Extract Preparation

Cell extract was prepared as described previously181. Briefly, an inoculum of E. coli BL21*
(DE3) strain was grown overnight in 5 mL of LB media at 37 ˚C and 280 rpm. The culture was
added to 100 mL of LB media and grew until OD600 reached 2.0. At 2.0 OD600, the 105 mL culture
was transferred to 1 L of LB media in a tunair baffled flask. At 0.6 OD600, isopropyl β-D-1thiogalactopyranoside (IPTG) was added to achieve a final concentration of 1 mM. Cells were
harvested at the end of the exponential growth phase using centrifugation at 6000 RCF for 10 min
at 4˚C. These were then washed with 4˚C Buffer A (10 mM Tris-acetate pH 8.2, 14 mM
magnesium acetate, 60 mM potassium glutamate, and 1 mM dithiothreitol (DTT)) and then
collected using an identical centrifugation cycle. Next, the pellet was re-suspended in Buffer A (1g
of cell/mL of buffer A), and homogenized with 3 passes through an EmulsiFlex French Press at
20000 psi. The homogenized cells were centrifuged at 12000 RCF for 30 min at 4 ˚C to clear the
lysate. The supernatant was incubated in a shaking incubator for 30 min at 280 rpm and 37 ˚C. The
extract was flash-frozen in liquid nitrogen for 60 seconds before being stored at - 80 ˚C.

5.2.3

Cell-free Protein Synthesis Reactions

CFPS reactions took place in a 96-well plate at 37 ˚C for 2 hours. PANOxSP was used as an
energy source (25% reaction volume of the cell extract, 1.2 nM plasmid, 12 to 15 mM magnesium
glutamate, 1 mM 1,4-diaminobutane, 1.5 mM Spermidine, 33.3 mM phosphoenolpyruvate, 10 mM
ammonium glutamate, 175 mM potassium glutamate, 2.7 mM potassium oxalate, 0.33 mM
nicotinamide adenine dinucleotide, 0.27 mM coenzyme A, 1.2 mM ATP, 0.86 mM CTP, 0.86 mM
GTP, 0.86 mM UTP, 0.17 mM folinic acid, 2 mM of all canonical amino acids with the exception
of glutamic acid181). CFPS protein yield was quantified by addition of 5 μM radiolabeled (U-14C)
leucine (PerkinElmer, Waltham, MA) to the CFPS reaction. Protein solubility was determined with
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TCA (trichloroacetic acid) precipitation while tracking radioactive 14C. Varying concentrations (0
to 200 μM) of ligands (dissolved in DMSO) were added to the CFPS reaction, and a DMSO control
was used with every test. In case of human sample testing, 20% and 10% of whole blood and urine
(v/v), respectively were added to the CFPS in addition to the EDC ligands.

5.2.4

RAPID Hormone Biosensor Assay

The biosensor assay was performed in 2 stages as described previously180. Stage 1: CFPS
of the biosensor protein in 96 well plate for 2 hours in the presence of 0 to 10 µM DPN, BPA,
TRIAC, or E2 dissolved in dimethyl sulfoxide (DMSO). The presence of the hormone receptor
ligand is thought to enhance correct folding of the biosensor protein, leading to increased activity
upon expression. For consistency, all CFPS reactions were adjusted to have final 5% (v/v) DMSO
concentration. Stage 2: After 2 hours, CFPS reactions first were diluted 13-fold into PBS buffer,
of which 25 µl was transferred into each well of a UV-transparent Corning® 96 well plate. To each
well, 175 µl of 228.6 µM nitrocefin in PBS was additionally added at the same time to achieve a
final nitrocefin concentration of 200 µM and overall 104-fold dilution of CFPS to eliminate signal
overflow. The plates were then directly quantified via plate reader (BioTek Synergy Mx) for a
nitrocefin-based beta-lactamase activity assay. Specifically, the absorbance was read at 390 and
490 nm wavelengths for unreacted and reacted substrate nitrocefin, respectively. Measurements
were repeated at 1 min intervals, with 10 sec shaking at each interval to mix, for 40 min. At the
end of the assay, the absorbance was read at 760 nm to provide a relative background level for the
assay. Nitrocefin conversion was determined for each ligand concentration at each point in time,
and the data from the time point with the largest difference in nitrocefin conversion was fit to a
four-parameter logistic function to obtain the effective ligand concentration (EC50)180. The log-
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linear response range is the logarithm of ligand concentrations that produces a linear response from
the sensor.
The quality of the assays was assessed using the signal-to-noise ratio (S/N) and signal to
background ratio (S/B) which were calculated using previously described methods183,184. The limit
of detection (LOD) was calculated according to IUPAC methodology which is the mean of the
zero-ligand measurement added to three times its standard deviation185.

5.2.5

Detecting Endocrine Disrupting Chemicals (EDC) in Human Samples Using
Biosensor Protein

Each CFPS reaction containing EDCs and human blood or urine was diluted 8-fold with
PBS. This diluted CFPS reaction was further diluted with PBS and nitrocefin mixture (final 32and 64-fold dilution for urine and blood, respectively). The final nitrocefin concentration was 200
µM. The activity of the reporter protein (β-lactamase) was measured as stated above. RNase
inhibitor was added to each reaction at 32 U per 40 uL reaction.

Results and Discussion

5.3.1

RAPID Biosensor Design for the hERβ

The modular, flexible nature of the RAPID biosensor is demonstrated for the first time by
adapting it to detect hERβ-specific endocrine disruptors. The biosensor, as illustrated in Figure
5-1, was constructed by replacing the human thyroid receptor β ligand-binding domain in our
previously reported sensor180 with the hERβ ligand-binding domain.
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5.3.2

Cell-free Protein Synthesis of the Reporter Fusion Protein

The RAPID biosensor protein (Figure 5-1) was expressed using an E. coli-based CFPS
system. The total protein production and solubility percentage were measured by incorporating 14C
radiolabeled leucine as described in the method section. As illustrated in Figure 5-2, the 120 kD
RAPID biosensor protein was expressed up to 650 µg/mL in 2 hr with an average solubility of
75%, which is similar to other proteins produced with CFPS. These results were similar to the
hTRβ construct which achieved 700 µg/mL in 3 hrs of protein production180.

Figure 5-2: CFPS of the RAPID biosensor protein. Protein production yield increases with increasing
reaction time. The solubility level remains relatively constant with increasing protein concentration.
Bars represent total protein yield and dashed line represents solubility percentage. The error bars
represent one standard deviation for n=3.

5.3.3

RAPID Biosensor Assay

The biosensor assay was performed as detailed in the methods section. Briefly, the two-step
process includes: 1) expressing of the RAPID biosensor protein construct using CFPS in the
sample to be tested and 2) performing nitrocefin colorimetric enzyme activity assay (Figure 5-1).
Biosensor performance was evaluated in the presence of four known endocrine disrupting
compounds: E2, DPN, BPA, and TRIAC (Figure 5-3). E2, DPN, and BPA are known XEs (EDCs
for the human estrogen nuclear hormone receptor) with different binding affinities, while TRIAC
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is a negative control (EDC for hTRβ). All assays with XEs produced dose-response graphs with
excellent quality. The EC50 for E2, DPN, and BPA were 124, 71, and 1443 nM, respectively, which
correspond well to the values obtained in our previous bacterial biosensor studies: 150, 190, and
1700 nM, respectively182. As expected the negative control, TRIAC, did not generate a statistically
significant result, which provides an indication of the estrogenic-chemical specificity of the assay.
The total time to perform the biosensor assay was 2.5 hr (2 hr performing CFPS and 30 reading
colorimetric assay), which is an order of magnitude less than the analogous cell based
biosensors186-188.

Figure 5-3: Dose-response graphs and statistical analysis results for the Estrogen receptor β RAPID
biosensor in the presence of E2, DPN, BPA, and TRIAC (negative control, normalized based on the
BPAE2 maximum response). The EC50 represents half-maximal effective concentration, k is the
slope factor, the Z' factor represents assay quality, S/N is the signal to noise ratio, S/B is the signal to
background ratio, and LOD is the limit of detection. The solid line represents fitted nitrocefin
conversion values, the square markers represent the measured values, and the error bars represent
one standard deviation for n=2. The concentrations over which the sensor exhibits a log-linear
response are 30-1000 nM, 300-10000 nM, and 10-700 nM for E2, BPA, and DPN, respectively.
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5.3.4

Engineering CFPS for Human Bodily Samples

To expand the applications of the biosensor, we previously showed that CFPS reactions
maintain protein synthesis capability in the presence of various environmental samples including
up to 45% by volume raw sewage. Although we demonstrated that CFPS reactions can produce
green florescent protein (GFP) in presence of human blood and urine, the protein yield was lower
in these samples, especially for urine180.
In this work, we engineered the CFPS reaction environment to improve protein yield in the
presence of urine and blood. Although only small amounts of protein are necessary for the
biosensor assay, increasing the protein yield reduces the quantity of reagents required to achieve
the same sensitivity.
Initially, we hypothesized that urea is the main component to hinder protein synthesis in
urine samples. The urea concentration in human samples is in a range of 0.1 to 0.8 M189-191 with
the average being 0.22 M191. To understand the effect of urea on CFPS, we synthesized the model
protein GFP in the presence of urea at concentrations between 0.001 to 1 M (Figure 5-4). The
results revealed that 0.1 M urea doesn’t have a significant effect on CFPS performance. Even
reactions with 0.5 M urea retained 40% protein synthesis capability. We should point out that our
previous work showed 10% urine, or about ~0.02 M urea, effectively eliminated CFPS180. These
results suggested that urea is not the main component in urine to negatively impact the CFPS.
We next hypothesized that RNase activity hinders protein synthesis in both urine and blood
samples192-194. To test this hypothesis, we performed CFPS of GFP in the presence of urine and
blood, and added murine RNase inhibitor as shown in Figure 5-5. Results revealed significant
improvement in protein synthesis. For instance, for 20% by volume urine sample, the GFP
production yield increased from less than 10% to more than 30%. The improvement was more
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significant for blood samples, as 10% by volume blood eliminated protein synthesis, but even 45%
by volume blood in CFPS containing RNase inhibitor retained 50% protein synthesis yield. The
results suggest significant RNase activity in the blood samples and to a lesser extent in urine
samples. Adding RNase inhibitors to CFPS reactions facilitates synthesis of sufficient biosensor
protein to detect ligands in up to 25% and 45% by volume urine and blood, respectively. These
higher volume percentages help to detect lower concentrations of ligands in the samples.

Figure 5-4: Effect of urea on CFPS of GFP. Error bars represent one standard deviation for n=3.

Figure 5-5: A. Effect of RNase inhibitor on CFPS of GFP in the presence of urine (top) and blood
(bottom). The blue bars in both graphs represent the improvements in protein production in the
presence of urine or blood with the addition of RNase inhibitor. The error bars represent one
standard deviation for n=3. B. Dose-response graph and statistical analysis results for the RAPID
biosensor in the presence of E2 and 20% by volume blood and 10% by volume urine. RNAse
inhibitors were added to both reactions. The solid line represents fitted nitrocefin conversion values,
the square markers represent the measured values, and the error bars represent one standard
deviation for n=2. The concentrations of E2 over which the sensor exhibits a log-linear response are
4-100 nM, and 8-300 nM, in urine and blood, respectively.
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5.3.5

RAPID Biosensor Performance in Human Urine and Blood

We chose 10% and 20% by volume of urine and blood, respectively, to investigate the
robustness of the RNAse-inhibited biosensor assay in the presence of these human medical
samples. As illustrated in Figure 5-5, the biosensor assay generated a dose-response with EC50 of
15 and 35 nM for E2 in presence of urine and blood, respectively. Both assays showed excellent
signal to noise ratios (21 and 12 for urine and blood, respectively). The EC50 is lower in the
presence of urine and blood, and this increased sensitivity could be attributed to a lower
background signal as less biosensor protein was produced (Figure 5-5). Previously, an increase in
RAPID sensitivity was also observed in the presence of raw sewage which similarly lowered the
biosensor protein production yields180. Additional engineering of the biosensor protein and CFPS
reaction environment may further increase assay sensitivity.

Conclusion
This work demonstrates that CFPS detection of hERβ ligands contributes several key
advantages to estrogenic EDC detection technology. First, CFPS detection of estrogenic EDCs is
rapid, requiring 2.5 hours, while conventional cell-based biosensors require days or weeks of
mammalian, yeast, or bacterial cell culturing before readout. The use of CFPS also removes cell
culturing steps from the detection workflow and enables rapid execution. This characteristic makes
the RAPID biosensor especially well-suited to high-throughput screening and portable detection
applications. Already, the RAPID biosensor has been deployed from lyophilized cell-free protein
synthesis components180, an important step toward achieving a portable, shelf-stable biosensor195.
Second, CFPS detection facilitates manipulation of the biochemical detection platform. This
means that the relative abundance of components can be optimized, or that disadvantageous
components can be inhibited. In this work, expression of the receptor construct was enhanced by
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the addition of RNAse inhibitors to the reaction environment, limiting human sample matrix
effects. This is significant because cell-based sensors can be adversely affected by the toxicity of
the sample matrix196. CFPS biosensors naturally overcome sample toxicity effects because they
lack viable cells. Lastly, CFPS detection is potentially very economic. Conventional protein
biosensors require protein expression followed by expensive purification. In contrast, no protein
purification is necessary to deploy the RAPID biosensor. The detection limits of the RAPID
biosensor are comparable to or better than a similar bacterial cell-based mechanism187.
Nevertheless, yeast and mammalian cell-based assays generally provide higher sensitivity
detection of estrogenic EDCs197. Yet, coupling the RAPID biosensor with sample concentration
techniques could produce a very rapid and sensitive detection tool. Here we expanded the
application of our RAPID biosensor to detect chemicals that interact with the human estrogen
receptor β (XEs). Specifically, we demonstrated the modular, flexible nature of this biosensor can
be exploited to expand the RAPID biosensor to additional nuclear hormone receptors and the
detection of other types of endocrine disrupting chemicals. The RAPID biosensor has the same
level of sensitivity as the analogous E. coli cell-based assays and many other reported cell-based
methods, but achieves this result in a fraction of the time needed for these assays. Finally, we
demonstrated for the first time that the RAPID biosensor can detect EDCs directly in human blood
and urine matrices, without sacrificing sensitivity, by adding RNAse inhibitors to the biosensor
assay.
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6

MECHANISM AND SIMULATION-GUIDED OPTIMIZATION OF CELL-FREE
HORMONE BIOSENSOR ASSAY

This chapter is an adaptation from the journal article by J. Porter Hunt, Jackelyn Galiardi, Tyler
Free, Seung Ook Yang, Daniel Poole, Joshua L. Anderson, David W. Wood, Bradley C. Bundy
titled “Mechanistic discoveries and simulation-guided assay optimization of portable hormone
biosensors with cell-free protein synthesis” in preparation for submission to Biotechnology
Journal. As the first author of this work, JPH performed experiments and simulations, analyzed
data, and wrote the manuscript. JPH is especially grateful to Tyler Free for lyophilizing the portable
emobidment of the hormone biosensor.

Introduction
Nuclear receptors (NR) influence numerous metabolic processes critical for growth,
homeostasis, and reproduction198. Chemicals which bind to NR and activate their cellular functions
include natural hormones, endocrine disrupting chemicals, and pharmaceuticals. In fact, drugs
which specifically target NR treat disorders from diabetes, cancer, and atherosclerosis to
emphysema, nausea, and osteoporosis199, 200. Additionally, industrial and commercial chemicals
have been identified as nuclear receptor ligands (NRL) and are classified among endocrine
disrupting chemicals (EDC), which interfere with correct NRL function.

Many chemicals

currently in use have not been screened for EDC activity201, 202, and it is estimated that the societal
cost of EDC exposure is high203. Thus, detection of NRL is a public health interest.
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Traditional methods to identify NRL include animal studies, mammalian cell cultures,
microbial sensors204, and competitive binding assays. However, these methods are not ideal for
high-throughput screening and portable detection because of their equipment requirements,
protracted assay durations, expensive preparations, and/or potential confounding toxicity
effects205-207.
An especially promising class of biosensors has recently leveraged the advantages of cellfree protein synthesis to create a rapid and robust detection assay for NRL. These assays are
liberated from many toxic matrix effects which plague cell-based assays and have demonstrated
ligand detection in raw sewage, urine, and whole blood208-212. The versatility of this construct to
integrate various LBD suggests potential for rapid detection and screening of ligands for many
different NR, including orphan receptors. At the heart of the assay is a chimeric fusion protein
construct comprising four domains: maltose binding protein, an engineered intein from Mtu, a
human or animal nuclear hormone receptor ligand-binding domain (LBD), and β-lactamase (βLac)
as a reporter protein (Figure 6-1). The assay first uses CFPS to express the sensor construct in the
presence of sample and then measures the resulting βLac enzymatic activity – greater βLac activity
results from higher hormone concentration. This assay can be completed in a few as 40 minutes
and has been deployed from lyophilized reagents. However, the molecular mechanism of this
sensor has not been elucidated, and additional insight could provide enhanced assay sensitivity.
Furthermore, while the potential for a portable hormone biosensor assay has been demonstrated
with lyophilization, the final embodiment has not yet been achieved – critical questions regarding
the sample size, dilution factor, and readable window remain.
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Figure 6-1: A. Schematic of biosensor construct and proposed molecular mechanism of hormone
response. The biosensor construct consists of (from N-terminus to C-terminus) the maltose binding
protein (MBP), the N-terminal mini intein domain, the nuclear receptor ligand binding domain, the
C-terminus mini intein domain, and the βLac reporter enzyme domain. Constructs employing the
human estrogen receptor β and human thyroid receptor β ligand binding domain (LBD) were used
in this study. B. Depiction of on-demand hormone assay, including photograph of lyophilized
hormone assay obtain after 5 minutes with nitrocefin. Step 1 consists of adding a sample with
unknown hormone concentration to the lyophilized CFPS. Step 2 is the CFPS reaction wherein
hormone biosensor construct is expressed in the presence of the sample. Step 3 is the addition of
enzymatic substrate with concomitant CFPS dilution. Step 4 is the biosensor readout which produces
an observable color change. Tubes shown are the result of hTRβ construct expressed with or without
12.5 µM TRIAC (see also Figure 6-8).

In this work, sensor constructs comprising either the human thyroid receptor beta (hTRβ)
or the human estrogen receptor beta (hERβ) LBD are studied using cell-free protein synthesis,
autoradiography, and western blotting, revealing that intein cleaving is hormone-dependent. Next,
mathematical simulations of enzyme kinetics suggest that this cleaving is integral to the biosensor
molecular mechanism for ligand-dependent signal-generation. Then, additional simulations of
enzyme kinetics facilitate optimization of the biosensor assay according to dilution factor,
substrate concentration, and assay duration. This approach enables more than 3-fold improvement
in the assay readable window and 2-fold improvement in assay signal strength. These discoveries
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facilitated the creation of a portable hormone detection assay and highlight the utility of CFPS for
studying complex protein activities. We anticipate that this work will facilitate rapid and portable
detection of natural hormones, therapeutic receptor modulators, and endocrine disrupting
chemicals, and inform the optimization of other future portable biosensor assays which employ
reporter enzymes.

Materials and Methods
Preparation of E. coli cell extract was performed as previously reported213. Briefly, BL21
StarTM DE3 E. coli cells were cultured at 37 °C in 2xYT medium, induced with 1 mM IPTG at
OD600=0.6, and harvested during the mid-log growth phase. Cells were recovered by
centrifugation, washed, then suspended in Buffer A (10 mM Tris-acetate, 14 mM magnesium
acetate, 60 mM potassium glutamate, and 1 mM dithiothreitol, pH 8.2) and homogenized with an
Avestin Emulsiflex B15 French Press Homogenizer (Ottawa, Ontario, CA). Lysate was clarified
by centrifugation at 12k RCF, incubated at 37 °C for 30 min, flash frozen into aliquots, and stored
at -80 °C.
17β-estradiol (E2; human estrogen receptor agonist), 3,3',5-triiodothyroacetic acid (TRIAC,
human thyroid receptor agonist) and amino acids were purchased from Millipore Sigma (Billerica,
Massachusetts).

Tris

Buffer

was

purchased

from

VWR

(Radnor,

Pennsylvania).

Phosphoenolpyruvate and nitrocefin were purchased from Cayman Chemical (Ann Arbor,
Michigan). Dithiothreitol was purchased from GoldBio (St. Louis, Missouri).
Preparation of E. coli cell extract was performed as previously reported213. Briefly, BL21
StarTM DE3 E. coli cells were cultured at 37 °C in 2xYT medium, induced with 1 mM IPTG at
OD600=0.6, and harvested during the mid-log growth phase. Cells were recovered by
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centrifugation, washed, then suspended in Buffer A (10 mM Tris-acetate, 14 mM magnesium
acetate, 60 mM potassium glutamate, and 1 mM dithiothreitol, pH 8.2) and homogenized with an
Avestin Emulsiflex B15 French Press Homogenizer (Ottawa, Ontario, CA). Lysate was clarified
by centrifugation at 12k RCF, incubated at 37 °C for 30 min, flash frozen into aliquots, and stored
at -80 °C. zz
Biosensor expression was performed as previously reported, and saturation of the assay
response was previously observed above about 5000 nM hormone214, 215. Lyophilized CFPS was
created by assembling cell extract and 12 nM plasmid DNA coding for the biosensor constructs
under T7 promoter with the following concentrations after rehydration: 15 mM magnesium
glutamate, 1 mM 1,4-diaminobutane, 1.5 mM spermidine, 33.33 mM phosphoenolpyruvate, 10
mM ammonium glutamate, 175 mM potassium glutamate, 2.7 mM potassium oxalate, 0.33 mM
nicotinamide adenine dinucleotide, 0.27 mM coenzyme A, 1.2 mM ATP, 0.86 mM CTP, 0.86 mM
GTP, 0.86 mM UTP, 0.17 mM folinic acid, and 2 mM of the other canonical amino acids. This
mixture was aliquoted into test tubes and lyophilized using the Labconco FreeZone 2.5L freeze
drier (Labconco Corp., Kansas City, Kansas) for 6 hours. Hormone dissolved in DMSO was
combined with aqueous sample to rehydrate the lyophilized CFPS reaction. CFPS reactions were
incubated at 37 °C for 1 hr or 3 hr, diluted with PBS, and finally with nitrocefin in PBS at the
indicated concentrations to the desired final dilution. The on-demand sensor result shown in Figure
6-1B was achieved with a 500x final dilution and a final nitrocefin concentration of 160 µM. Fresh
CFPS reactions were assembled and incubated as above without lyophilization.
Reactions testing post-translational allosteric activation of the sensor constructs were
expressed for three hours (to completion of translation) before E2 or TRIAC in DMSO were added
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to the indicated concentrations. The final concentration of DMSO was 5% (v/v). These reactions
were then incubated at 37 °C for 30 min before βLac enzymatic analysis.
Radiolabeled CFPS reactions were assembled as above with the addition of 5.25 µM C14
leucine (Moravek, Brea, California). Following the reaction, CFPS liquid was dried onto filter
paper tickets, precipitated with 5% trichloroacetic acid, and analyzed by liquid scintillation
counting using the Beckman LS 6000TA (Beckman/Perkin Elmer, Waltham, Massachusetts).
Radiolabeled CFPS reactions were analyzed with NUPAGETM 10% Bis-Tris protein gel
(Invitrogen, Waltham, Massachusetts) according to manufacturer’s instructions. Resulting gels
were dehydrated and used to expose Kodak CarestreamTM BioMaxTM autoradiography/light film
for 3 to 5 days. Western blot samples were electrophoretically analyzed identicaly to radiolabeled
samples, and then transferred to nitrocellulose membrane using manufacturer recommendations
on the Criterion Blotter Transfer Cell (Bio-rad, Hercules, California). Proteins were labelled with
rabbit-anti-β-lactamase primary antibody (kind gift from Professor Dario Mizrachi). Primary
antibody was labelled using IRDye 800CW secondary antibody (LI-COR 926-32211) and imaged
with the LI-COR Odyssey imaging system. Densitometry was performed with Image J (Figure
6-4A).
Upon receipt, nitrocefin was suspended in DMSO to 20 mM, aliquoted, and stored at 80 °C as working stock. βLac enzymatic activity assays were performed at 30 °C in clear, 96-well
plates (Corning, Corning, New York) wherein the hydrolysis of nitrocefin and formation of
enzymatic product were monitored every 1 or 3 minutes as the OD390 and OD490. These
measurements were normalized with final OD values for each well and converted to nitrocefin
hydrolysis product concentration for analysis. Mathematical simulations were programmed with
Python and parameter fits were calculated using least-squares regression.
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Results and Discussion
Previous efforts to elucidate the molecular mechanism of the protein biosensor construct
in bacteria have postulated a potential allosteric activation mechanism but have been complicated
by microbial viability. Cell-free protein synthesis of the biosensor decouples construct expression
and ligand-dependence from microbial metabolism and liberates the sensor protein for direct
biochemical analysis following protein translation. Greater mechanistic understanding could lead
to enhanced sensor performance, and a study of the sensor mechanism was undertaken using cellfree protein synthesis. Constructs employing hERβ and hTRβ LBD as the sensing element and
extended spectrum β-lactamase (βLac) as the reporter protein were chosen for this investigation
(Figure 6-1A).

6.3.1

Role of Intein Domain in Cell-free Biosensor Expression

In their native environment, NR function via ligand-induced allosteric conformational
changes which originate in the LBD and result in repositioning of helix 12216, 217. This sensor
construct is designed such that helix 12 is linked directly to the N-terminus of the C-terminal intein
segment, with the reporter protein linked directly to the C-terminus of the intein. It has been
hypothesized that the intein domain transduces the ligand-binding conformational change from the
NR LBD to the reporter protein. To test this hypothesis using CFPS, constructs containing the
maltose binding protein, NR LBD, and βLac, but omitting the intein domain, were expressed and
then assayed for βLac activity using nitrocefin. These constructs resulted in low soluble expression
yield and lost ligand-dependent reporter activity (Figure 6-2A,B), similar to previous cell-based
results. This observation confirms the critical role of the intein in construct performance.
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Figure 6-2: A. Soluble expression yield of biosensor construct omitting intein domain in the presence
and absence of hormone TRIAC. Solid bars represent total protein expression yield and white bars
represent soluble protein expression yield. Error bars represent one standard deviation for n=2 CFPS
reactions. B. βLac enzymatic activity of biosensor construct from A as determined by percent
hydrolysis of substrate nitrocefin after 37 min assay duration. C. βLac enzymatic activity of CFPS
biosensor construct with the indicated hormone (E2/TRIAC) concentration added after CFPS
expression. βLac enzymatic activity was measured as percent initial nitrocefin hydrolysis after five
minutes and three minutes assay duration for hERβ and hTRβ constructs, respectively.

6.3.2

Allosteric Investigation of Biosensor Construct

Next, the allosteric character of the biosensor protein mechanism was investigated. Fulllength sensor construct was first expressed in CFPS without ligand. Next, ligand was added to the
constructs, incubated to allow binding, and reporter activity was assessed. In contrast to biosensor
expressed in the presence of ligand, these constructs did not show ligand-dependent reporter
activity (Figure 6-2C). Interestingly, the fraction of protein that expresses in soluble form is not
affected by the concentration of ligand present in the reaction213, 214. These results uncover an
important component of the sensor’s ligand response: the biosensor protein must be expressed in
the presence of ligand to create an activated reporter enzyme. This suggests that, during translation,
ligand-bound constructs may fold into an enzymatically active conformation, while the apo form
of the construct may traverse an alternative folding pathway, thereafter, energetically prohibited
from forming a more-active conformation. The fact that the construct must be expressed in the
presence of the sample highlights the critical role of CFPS for on-demand sensing: pre-expressing
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and lyophilizing biosensor construct will not enable ligand detection; only by lyophilizing poised
CFPS translation components can this sensor be deployed on-demand. CFPS also enables synthesis
of the construct in complex matrices which are potentially toxic to microbe growth214, 215. While
these results also suggest that the construct is not allosterically activated like the native NR,
previous experiments confirm that the affinity of the ligand for the LBD determines the strength
of the biosensor’s response, and correct distinction between NR agonists and antagonists has even
been reported209. This assay therefore retains remarkably high fidelity with native NR signaling.

6.3.3

Catalytic Cleaving of Sensor Reporter Domain

Although Mtu RecA mini inteins similar to that employed by this construct exhibit catalytic
cleaving activity218, the role of catalytic cleaving in the mechanism of this fusion biosensor, a
functionality that might be engineered to enhance ligand sensitivity, has not previously been
established. To investigate the role of intein cleaving in sensor performance, the hTRβ and hERβ
constructs were expressed in the presence of radioactive C14 leucine at increasing ligand
concentrations then analyzed on denaturing agarose gel. All reactions yielded between 3 and 4 µM
biosensor fusion protein, regardless of ligand concentration, which is consistent with previous
results214, 215. Bands containing radioactive leucine were then visualized with autoradiography
(Figure 6-3A). While the results indicate an abundance of full-length, intact sensor constructs (120
kDa), they also clearly demonstrate an appreciable degree of construct cleaving. Significantly, a
radioactive band appears at ~30 kDa, which becomes more intense at higher ligand concentrations.

73

Figure 6-3: A. Autoradiograph of hERβ and hTRβ biosensor constructs. Cleaved β-Lactamase (βLac)
domain is visible at ~30 kDa. Lanes 1-6 analyze hERβ construct expressed with the following E2
concentrations: 1= 0 nM, total construct; 2= 0 nM soluble construct; 3= 2400 nM, total construct; 4=
2400 nM, soluble construct; 5= 200,000 nM, total construct; 6= 200,000 nM, soluble construct. Lanes
7-12 analyze hTRβ construct expressed with the following TRIAC concentrations: 7= 0 nM, total
construct; 8= 0 nM, soluble construct; 9= 1700 nM, total construct; 10= 1700 nM, soluble construct;
11= 200000 nM, total construct, 12= 200000 nM, soluble construct. B. Western blot for βLac with
biosensor constructs. White indicates the βLac protein. Lane 1= No-plasmid control reaction. Lanes
2-6 analyze hTRβ construct expressed with the following TRIAC concentrations: 2= 0 nM TRIAC;
3= 10 nM TRIAC; 4= 100 nM TRIAC; 5= 300 nM TRIAC; 6= 10,000 nM TRIAC. Lanes 7-11 analyze
hERβ construct expressed with the following E2 concentrations: 7= 0 nM; 8= 10 nM; 9= 100 nM; 10=
300 nM; 11= 10,000 nM.

For reference, the molecular weight of the reporter protein, βLac, is 29.9 kDa. To confirm the
identity of this ligand-dependent band, samples of these constructs were analyzed using western
blot with primary antibody specific to βLac (Figure 6-3B). These results confirm that this band is
the cleaved βLac reporter domain and that its intensity increases with ligand concentration.
Importantly, ligand-saturated reactions (10000 nM TRIAC and E2) yielded about 10 times the
amount of cleaved beta-lactamase reporter when compared with the no-ligand reactions, as
analyzed by densitometry. Furthermore, the cleaved βLac domain likely represents between 0.2%
to 2.0% of the βLac still covalently attached to intact, full-length construct (Figure 6-4A). These
results indicate that constructs expressed in the presence of hormone are more likely to cleave than
those expressed without hormone.
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Figure 6-4: A. Densitometry analysis of western blot results shown in Figure 2. Densitometry of bands
representing free βLac are boxed in blue. B. Enzymatic activity on nitrocefin of free βLac and both
the hTRβ and hERβ constructs. The indicated concentration of free βLac was determined by
radiolabeling with C14 leucine during CFPS, and the indicated concentrations of cleaved βLac in the
hTRβ and hERβ samples were determined by radiolabeling of the whole construct and assuming a
catalytic cleaving incidence of 2%. Error bars represent one standard deviation for n=2 reactions.

6.3.4

Kinetic Analysis Elucidates Sensor Molecular Mechanism

The results of the western blot experiment suggest that catalytic cleaving of the reporter
domain could be significant to the molecular mechanism of hormone dependence. To further
explore the extent to which cleaved βLac contributes to the enzymatic activity of the biosensor,
free βLac was expressed in CFPS then assayed for enzymatic activity alongside hTRβ and hERβ
construct expressed with CFPS in the presence of 10000 nM TRAIC and 10000 nM E2,
respectively. The results of this analysis are remarkably consistent with sensor enzymatic activity
predominantly generated by cleaved reporter domain (Figure 6-4B). If 2% of the biosensor
construct cleaved the reporter domain, the concentration of free βLac in the hTRβ and hERβ
construct samples would have yielded 11.3 pg/uL and 9.5 pg/uL βLac, respectively. By
comparison, the concentration of free βLac which yielded similar enzymatic activity curves was
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14.0 pg/uL. This suggests that cleaved βLac reporter contributes significantly to the sensor’s
hormone-dependent enzymatic signal.
To investigate this factor in greater detail, kinetic analysis with a closed-form solution to
the Michaelis-Menten equation219 was employed with βLac activity data from biosensor construct
and free βLac alone (Figure 6-5). The best-fit equations to enzymatic activity data indicate a 6.7fold increase in the reporter enzyme concentration parameter [E]x when comparing the 10000 nM
TRIAC reactions with the no-hormone reactions (Figure 6-5). By comparison, free βLac at a 10fold difference in enzyme concentration resulted in a 10-fold difference in the best-fit enzyme
concentration parameter [E]x. These latter results suggest that a 10-fold difference in enzyme
concentration parameter [E]x would be observed if cleaved reporter were entirely responsible for
the sensor’s hormone-dependent enzymatic response. At the same time, this ratio is less than 10,
suggesting that the true mechanism is not more responsive to ligand than a purely cleavingmediated mechanism. We therefore conclude that catalytic cleaving is likely responsible for the
majority, though not the entirety of construct enzymatic activity. Furthermore, we conclude that
catalytic cleaving is a critical part of the intein-mediated performance of the biosensor.
Overall, these results suggest that catalytic cleaving of the reporter domain is the primary
mechanism for hormone-dependent enzymatic signal generation. It is hypothesized that the
biosensor construct generates a hormone-dependent enzymatic response through co-translational
hormone-stabilized folding of the intein into conformations which favor catalytic cleaving of the
polypeptide backbone. Cleaved βLac is expected to be more enzymatically active than uncleaved
βLac because of the reduction in steric hindrance to substrate diffusion and potential destabilizing
effects of the other construct domains. These results suggest that a hormone-induced
conformational change which increases reporter domain activity without catalytic cleaving, though
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possible, is unlikely to be the most important contributing mechanism. These discoveries hold
promise for expanded and improved biosensing of hormones and endocrine disrupting chemicals.
The consistency between the mechanistic observations of hTRβ and hERβ constructs shows
potential for screening ligands of orphan NR in the future. Furthermore, protein engineering
techniques may increase ligand-dependent activity by enhancing the rate of ligand-induced
cleaving of the βLac reporter enzyme. It is therefore anticipated that this work will enable
improved sensing and screening of natural hormones, therapeutic receptor modulators, and
endocrine disrupting chemicals.

Figure 6-5: Kinetic enzymatic analysis of hormone biosensor readout. A. closed-form solution to the
Michaelis-Menten equation, where [P]x(t) is the concentration of enzymatic product as a function of
assay duration and hormone concentration, t is time, [S]0 is the initial substrate concentration, Km is
the Michaelis-Menten constant, kcat is the catalytic rate constant, and [E]x is the putative active βLac
concentration as a function of hormone concentration. W{…} designates the real branch of the
lambert w function for the argument. The given kinetic parameters were obtained by the fit
represented in B and D. B. Data and equation fit to the results of the hormone biosensor assay. Each
data trace represents one CPFS reaction with the indicated hormone concentration. The parameters
Km and kcat were fit by least-squares to the data set as a whole, with [E]x simultaneously fit to the
result for each hormone concentration, with values given in the accompanying table. The ratio of
enzyme concentration parameter estimate ([E]x) between 10000 nM TRIAC and 0 nM TRIAC is 6.7.
C. Enzymatic activity of βLac with enzyme concentrations differing by exactly 10-fold. The same
kinetic parameters Km and kcat were obtained from a fit to both data series with independent [E]x
values fit to each series. These values are given in the accompanying table. Data traces represent
duplicate reactions. The true concentration of assayed βLac was 5.3 and 0.53 nM as determined by
radiolabeling of βLac. D. Biosensor βLac enzymatic assay readout represented as sensor signal.
Sensor signal is defined as the difference between the enzymatic activity of biosensor CFPS in the
presence of hormone and the enzymatic activity of CFPS in the absence of hormone.
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6.3.5

Assay Optimization and Creation of On-demand Hormone Biosensor

An exciting feature of cell-free biosensors is that the reporter protein is not contained
within cells, and thus is amenable to straightforward optimization of the assay readout. Such
optimization is necessary for a field-deployable sensor that would be sensitive to a number of
important operating parameters. Factors which significantly affect readout include the volume and
concentration of enzyme substrate added to the assay (or CFPS dilution factor) and the time after
initiation of the assay that the signal is obtained. Recognizing an excellent mathematical
representation of the sensor readout (Figure 6-5), this work next sought to achieve a general
optimization across CFPS dilution factor, substrate concentration, and readout time in order to
maximize assay sensitivity and provide practical operating parameters for a field-deployable assay.
The prohibitive sample space required by a purely experimental optimization approach highlighted
the advantages of a mathematical approach confirmed by select experiments. Importantly, the
closed-form solution to the Michaelis-Menten equation already showed excellent agreement with
the results of the βLac enzymatic assay (Figure 6-5).
First, biosensor signal was defined as the difference in enzymatic product concentration
(hydrolyzed nitrocefin in this case) between ligand and no-ligand sensor reactions (Figure 6-5C).
This measure is determined by the optical density measured by a spectrophotometer and an
absorbance standard curve for a quantitative rigorous readout, or as an observable color change
for a more qualitative readout. Notably, these data show that the intensity of the readout signal
reaches a short-lived maximum, after which the signal disappears. This observation highlights the
significance of the assay read time in obtaining the strongest possible signal for a target ligand
concentration. In the case of an on-demand, point-of-care embodiment, the volume and
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concentration of nitrocefin to add to the CFPS reaction, and the time at which to record an
observation, are important assay parameters.

Figure 6-6 Results of biosensor assay simulations using the closed-form solution to the MichaelisMenten equation presented in Figure 2. A. Maximum sensor signal as a function of initial substrate
concentration. The maximum signal is the maximum in the curves shown in Figure 6-5C and is the
difference between the time-course curves with and without hormone. B. Assay duration in seconds
until maximum sensor signal as a function of initial substrate concentration and CFPS dilution factor.

Next, the effect of initial substrate concentration on the assay signal strength was explored,
assuming that the amount of cleaved reporter protein between ligand and no-ligand sensor
reactions remains fixed. These results indicate that the expected maximum achievable signal
strength, and therefore assay sensitivity, increases with increasing substrate concentration (Figure
6-6A). The expected time at which the maximum signal is achieved as a function of both enzyme
dilution and substrate concentration was also investigated (Figure 6-6B). Finally, the expected
signal strength as a function of time and initial substrate concentration at three different enzyme
dilutions was represented experimentally and mathematically. Enzymatic activity of thyroid
biosensor expressed in the presence of 0 µM and 10 µM TRIAC was assessed with either 170 µM
or 340 µM nitrocefin at 50, 100, and 200 fold dilution. Experimental results are consistent with
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simulated biosensor signal results (Figure 6-7A). Importantly, increasing nitrocefin concentration
from 170 µM to 340 µM increased the biosensor reporter signal by 2-fold.

Figure 6-7: A. Data and solution fit of biosensor signal strength over time at 170 µM or 340 µM
nitrocefin and 50, 100, and 200 fold dilution. Data traces for duplicate experiments are shown. B.
Simulation of biosensor signal strength over time at 50, 100, and 200 fold dilution and increasing
substrate concentration.

These results clearly indicate that a higher reporter substrate concentration results in a
higher assay signal strength, a twofold increase in sensor signal strength when 340 µM nitrocefin
is used instead of 170 µM. This advantage is only expected to be limited by substrate solubility.
Next, these results show that an increased dilution factor increases the time window during which
a strong assay signal is readable. A dilution factor of 200x was the most advantageous of those
tested experimentally, increasing the readable time window by at least 5-fold while only delaying
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the onset of maximum signal readout by about 5 minutes. This result indicates that the reaction
which expresses the biosensor construct requires only a very small sample size because of the large
dilution factors which are required to generate a discernable readout within a reasonable time
window. This feature would be especially advantageous for detection in patient samples at pointof-care.
Guided by these results, an on-demand hormone assay was created in which CFPS
machinery and energetic molecules were first lyophilized into a test tube. Next, the CFPS reaction
was reconstituted with aqueous sample with and without hormone and incubated for 1 hr. Finally,
the CFPS reaction was diluted, and the visible color change was observed after 5 minutes (Figure
6-8). More precise quantification of biosensor signal can be obtained with a portable
spectrophotometer.

Figure 6-8: Photographed results of the on-demand hormone biosensor assay. A. Lyophilized pellet
for on-demand hormone biosensor. B. CFPS liquid from lyophilized pellet rehydrated with TRIAC
sample. C. Result of hTRβ hormone biosensor reconstituted in aqueous sample without hormone.
This photograph was captured five minutes after adding nitrocefin. D. Result of hormone biosensor
reconstituted with 12.5 µM TRIAC in aqueous sample. This photograph was captured five minutes
after adding nitrocefin.
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Conclusion
This work highlights the utility of CFPS for studying and optimizing complex protein
mechanisms. CFPS, autoradiography, and western blots of the biosensor construct show greater
cleaving incidence with higher hormone concentrations in construct expressed with cell-free
protein synthesis. This observation suggests that intein catalytic cleaving activity is critical to the
construct’s hormone response. Mathematical simulations of enzyme kinetics confirm that cleaved
reporter protein contributes the majority of biosensor enzymatic signal. Taken together, these data
indicate that a catalytically active intein conformation is critical for hormone-dependent signal
generation in both the estrogen and thyroid sensor constructs. Conversely, cell-free biosensor
constructs omitting the intein domain or expressed in the absence of ligand lose ligand-dependent
signal generation. Additionally, mathematical simulations predict, and experiments confirm that
increased substrate concentration and dilution factor improve assay signal strength by 2 fold and
increase assay signal duration by 3 fold. An on-demand hormone test was created using these
design insights. Importantly, these assay optimization principles may be usefully generalized to
other portable biosensors which rely on conversion of substrate to product for signal readout –
substrate concentration should be maximized for maximum sensor signal strength. Furthermore,
the on-demand test reported herein is an important step toward rapid and field-deployable
biosensors of endocrine disrupting chemicals, therapeutic receptor modulators, and natural
hormones.
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7

ENGINEERING CELL-FREE METABOLISM FOR DETECTION OF LGLUTAMINE IN HUMAN SERUM

This chapter is an adaptation from the article by J. Porter Hunt, R. Jordan Barnett, Hannah
Robinson, Mehran Soltani, J. Andrew D.Nelson, and Bradley C.Bundy entitled, “Rapid sensing of
clinically relevant glutamine concentrations in human serum with metabolically engineered E.
coli-based cell-free protein synthesis” published in Journal of Biotechnology, Volume 325, 10
January 2021, Pages 389-394, https://doi.org/10.1016/j.jbiotec.2020.09.011. JPH conceived and
directed this work, and is grateful to R. Jordan Barnett, Hannah Robinson, Mehran Soltani, and J.
Andrew D. Nelson for their contributions. JPH is grateful to the Simmons Center for Cancer
Research at BYU for funding to pursue this work as a fellow of the center.

Introduction
The amino acid L-glutamine (Gln) serves critical physiological functions in metabolism,
intestinal health, immune function, and cell signaling. Not surprisingly, altered serum Gln
concentration has been associated with a variety of disorders and diseases, including severe
infection220,221, anorexia nervosa222, chronic kidney disease223, and diabetes224-226. Additionally,
the significance of Gln metabolism in cancer is attracting increasing attention. Studies suggest that
degradation of Gln by asparaginase is an important component of the latter’s anti-leukemic
efficacy227,228. A host of recent work on cancer Gln metabolism229-232 has led to six clinical trials
which target Gln in treatment for non-small cell lung cancer, renal cancer, colorectal cancer,
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melanoma, myelodysplastic syndrome, and metastatic solid tumors233 and suggests that
modulating Gln metabolism could be a hallmark of future cancer treatment. Thus, quantifying
serum Gln levels is a potentially critical tool for a number of disease diagnoses and treatments234236

.
Despite this clinical potential, measuring serum Gln levels is challenging. Current methods

rely on high-performance liquid chromatography237 or magnetic resonance spectroscopy, which
require extensive preparation and expensive overhead equipment, precluding routine clinical use.
Commercially available enzyme assays remain expensive and are subject to the confounding
effects of ammonia, an elevated serum constituent during therapeutic Gln depletion238. As a
consequence, Gln quantification may be underutilized for diagnosing and treating these diseases,
and alternative technologies could be transformational.
Cell-free protein synthesis (CFPS) is an emerging sensing platform with manifold
promising applications239-243. The open transcription-translation reaction environment facilitates
exquisite system optimization and control, and CFPS biosensors have been engineered to operate
on the transcription, translation, and protein-folding levels25. Sensing platforms formulated from
E. coli lysates leverage the robustness of bacterial gene expression, can be lyophilized to create
portable indicators245-248, and have demonstrated utility in a variety of environmental and
biological sample matrices240,249. Compared with their microbial counterparts, CFPS biosensors
eliminate sample transport limitations as well as the risk of releasing genetically modified
microbes250. Additionally, they enable more rapid readouts and detection in matrices that are toxic
to microbes.
Recent work demonstrated complementary CFPS reactions for quantifying amino
acids251,252. However, this approach was unable to quantify Gln concentrations due to the residual
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activity of native metabolic pathways. In this work, we engineer residual E. coli amino acid
metabolism using an irreversible Gln synthetase inhibitor to create a CFPS sensor for Gln. We
further demonstrate the utility of this approach by validating the Gln assay in human serum. Pointof-care quantification of serum Gln enabled by this CFPS approach could be exceedingly useful
for diagnosing and treating individuals suffering from severe infection, anorexia nervosa, chronic
kidney disease, diabetes, and cancer.

Materials and Methods

7.2.1

Cell Extract Preparation

E. coli cell extract containing bacteriophage T7 RNA polymerase was prepared as
previously described253. Briefly, 5 mL overnight culture of BL21 StarTM (DE3) was added to 100
mL 2xYT. When OD600 reached ~2.0, culture was transferred to 900 mL 2xYT. 1 L cultures were
induced with 1 mM IPTG at OD600 0.4-0.6 and harvested at OD600 ~2.5. All bacterial cultures were
incubated at 37°C and 280 RPM. Cells were homogenized with three passes at 21000 psi using the
EmulsiflexB15 French press homogenizer (Avestin, Ottawa, CA) and centrifuged at 12000 RCF
for 10 min. Clarified lysate was then incubated at 37°C and 280 RPM for 30 min. Cell extract was
dialyzed using 14 kDa MW cut-off cellulose membrane tubing (MilliporeSigma, Billerica, MA)
for 4 hr at 4°C immediately following incubation at 37°C.

7.2.2

Sensing Cell-free Protein Synthesis Reactions

Cell-free protein synthesis reactions were formulated in 96-well plates with the following
specifications: 25% (v/v) cell extract, 12 nM pY71-sfGFP254, 10-20 mM magnesium glutamate
(concentration adjusted for optimal protein yield), 1 mM 1,4-diaminobutane, 1.5 mM spermidine,
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40 mM phosphoenolpyruvate, 10 mM ammonium glutamate, 175 mM potassium glutamate, 2.7
mM potassium oxalate, 0.33 mM nicotinamide adenine dinucleotide, 0.27 mM coenzyme A, 1.2
mM ATP, 0.86 mM CTP, 0.86 mM GTP, 0.86 mM UTP, 0.17 mM folinic acid, 6 mM aspartate
(Asp), 6 mM asparagine (Asn), and 2 mM of the 16 remaining proteinogenic amino acids. Gln was
omitted from Gln-sensing reactions. Human serum was thawed on ice upon receipt from Gemini
Bio Products (Sacramento, CA) and immediately refrozen into aliquots before storage at -80 °C.
Serum aliquots were thawed on ice immediately prior to CFPS and added to a final volume fraction
of 14%. Murine RNAse inhibitor (New England BioLabs, Ipswich MA) was added to a final
concentration of 0.8 U/µL CFPS to all reactions containing human serum250. Reactions were
incubated at 37°C in a BioTek SynergyMX plate reader, shaken for 30 seconds, and analyzed for
fluorescence every 4-6 minutes at 480/510 nm excitation/emission wavelengths. Results were
obtained after 60 minutes. Assay signal strength was calculated as the ratio of GFP relative
fluorescence units (RFU) at saturating Gln concentrations to the GFP RFU at 0 µM Gln.

Results
Motivated by the opportunity to improve diagnosis and treatment for the discussed diseases,
we sought to create a rapid E. coli-based cell-free protein synthesis (CFPS) Gln sensor which could
be engineered to deliver point-of-care quantification. First, we initiated GFP-producing CFPS
reactions omitting Gln. In principle, the translation machinery of these reactions polymerizes
amino acids until the 69th codon of GFP’s transcript, which codes for Gln. In the absence of tRNA
aminoacylated with Gln, the ribosome stalls and a truncated polypeptide is released. In contrast to
this expectation, we and others observed that CFPS reactions omitting Gln achieve similar yields
to those with all 20 proteinogenic amino acids251 (Figure 7-1). This suggests that the eight
glutamine molecules necessary for each full-length GFP molecule are readily synthesized by
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residual E. coli amino acid metabolism in the CFPS reaction, possibly by glutamine synthetase
(EC 6.3.1.2) (GLNS) (Figure 7-2, Figure 7-3).

Figure 7-1: Cell-free protein synthesis (CFPS) of GFP is maintained when L-glutamine (Gln) is
omitted. A. Illustration of CFPS and hypothesized pathway of Gln synthesis by native glutamine
synthetase (GLNS). B. GFP fluorescent signal produced by CFPS reactions initiated with or without
2 mM Gln. Relative fluorescence units (RFU) indicate the amount of GFP synthesized in CFPS. Data
was obtained after 1 h reaction and error bars represent one standard deviation for n = 2 CFPS
reactions.

Figure 7-2: A. Chemical structure of glutamate (Glu), the enzymatic substrate of glutamine
synthetase (EC 6.3.1.2) (GLNS), its enzymatic product, glutamine (Gln), and methionine sulfoximine
(MSO), a competitive inhibitor of GLNS. B. E. coli Gln biosynthesis pathway and inhibition of GLNS
activity by MSO, including other E. coli enzymatic reactions relevant to Gln metabolism.
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Figure 7-3: Glutamine Synthetase (EC 6.3.1.2) (GLNS) enzymatic activity and inhibition. A.
Chemical reaction catalyzed by glutamine synthetase, converting glutamate (Glu) and ammonia to
glutamine (Gln). B. Mechanism of inhibition of GLNS by methionine sulfoximine (MSO), a
transition-state analog of the acyl-phosphate intermediate that remains in the GLNS active site.

7.3.1

Engineering CFPS with Methionine Sulfoximine

We hypothesized that the abundance of glutamate (>200 mM), combined with residual
GLNS activity in CFPS, produced Gln needed for translation during CFPS. Methionine
sulfoximine (MSO) has been identified as a potent irreversible inhibitor of GLNS255 and we further
hypothesized that adding MSO to CFPS could enable the desired Gln detection. We first verified
that MSO has little effect on CFPS expression yield at concentrations up to 80 mM in the presence
of 2 mM Gln (Figure 7-4A).
Next, we demonstrated that adding MSO to CFPS reactions - wherein Gln is initially
omitted - results in GFP production as a function of the Gln concentration (Figure 7-5). This
response appears to exhibit a differentiable range below ~300 µM Gln.
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Figure 7-4: A. Effect of methionine sulfoximine (MSO) on E. coli cell-free protein synthesis wherein
Gln and other proteinogenic amino acids are added at 2 mM. Data traces represent n=2 independent
cell-free reactions at each MSO concentration. B. Effect of MSO on glutamine (Gln) sensor signal
strength. Signal strength is calculated as the ratio of GFP RFU at saturating Gln concentrations to
the GFP RFU at 0 µM Gln. Data traces represent n=2 independent cell-free reactions at each MSO
concentration. Data was obtained after 1 hr cell-free reaction. Blue line represents linear regression,
red bands represent 95% confidence of fit, dashed black bands represent the 95% confidence range
for a single-point prediction.

Notably, the signal-to-noise ratio of the assay increased linearly to ~10 with increasing the MSO
concentration up to 70 µM (Figure 7-4B) and was also enhanced by increasing overall protein
expression yields (Figure 7-7). A least-squares fit of the CFPS GFP yield as relative fluorescence
units (RFU) to the Hill equation yields an EC50 and Hill coefficient of 154 µM and 2.1,
respectively (Figure 7-5).
The effect of dialyzing cell extract on CFPS Gln dependence was investigated under the
hypothesis that dialysis removes residual free Gln from the extract and might increase the Gln
sensitivity of the assay. However, dialysis did not improve the limit of detection, further supporting
the Gln synthesis hypothesis (Figure 7-7). This suggests that residual Gln metabolism in CFPS is
primarily responsible for the minimal assay background signal rather than of free Gln remaining
in the extract.
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Figure 7-5: GFP production level by CFPS is dependent on Gln levels when the GLNS-inhibitor MSO
is included. A. Illustration of protein synthesis with methionine sulfoximine (MSO), a potent inhibitor
of GLNS. Top: When Gln is not added to CFPS and MSO inhibits GLNS, Gln is unavailable for
aminoacylation and polypeptide linkage by the ribosome which prevents the synthesis of full-length
GFP at high yields. Bottom: If a sample which contains Gln is added to the MSO-containing CFPS,
Gln is more available to the ribosome resulting in higher yields of full-length GFP. B. Results of CFPS
Gln sensor assay. Reactions omitted Gln as a reagent but included 70 mM MSO. Aqueous samples of
known Gln concentrations were added to the CFPS reaction with the x-axis representing the final
concentration of Gln in the CFPS reaction (ranging from 0 to 2400 μM). Each data point represents
a CFPS reaction after 1 h with n = 2 at each Gln concentration. Relative fluorescence units (RFU)
indicate the amount of GFP synthesized in CFPS. The solid green line represents least-squares
regression of the data to the Hill equation, resulting in an EC50 value of 154 μM and a Hill coefficient
of 2.1. Inset plots linear regression of the data. Solid blue line represents the fit, solid red bands
represent the 95 % confidence of fit, and dashed black bands represent the 95 % confidence range
for a single-point prediction.

7.3.2

Analytical Features of the Assay

The detectable range of this Gln assay is fortuitously suited to quantifying physiological
Gln concentrations, which may range between 200 and 1400 µM222,223, and a Gln signal can be
detected after as few as 20 min CFPS, an assay duration which is similar to rapid HPLC protocols37.
We tested the performance of this assay in the presence of 14% (v/v) human serum and observed
a Gln response nearly identical to reactions initiated with aqueous samples (Figure 7-6). The Hill
equation also effectively models the assay Gln response in the presence of human serum, with
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parameter estimates of 2.1 and 100 µM for the Hill coefficient and EC50 values, respectively
(Figure 7-6). These results feature a highly linear region amenable to detecting clinically relevant
concentrations of Gln, and a detection limit near 10 µM. The CFPS response approaches a
maximum after ~400 µM Gln and the linear range extends beyond the assay’s EC50 of 100 µM.

Figure 7-6: Results of CFPS Gln sensor assay in the presence of human serum. Reactions omitted
Gln as a reagent but contained 70 mM MSO, RNAse inhibitor, and 14 % (v/v) human serum with
increasing Gln concentrations. The x-axis represents the corresponding Gln concentration in the
CFPS reaction. Each data point represents a CFPS reaction after 1 h with n = 2 at each CFPS Gln
concentration. Relative fluorescence units (RFU) indicate the amount of GFP synthesized in CFPS.
Solid blue line represents least-squares regression of the data to the Hill equation, resulting in an
EC50 value of 100 μM and a Hill coefficient of 2.1. Inset shows linear regression of the data. Solid
blue line represents the fit, solid red bands represent the 95 % confidence of fit, and dashed black
bands represent the 95 % confidence range for a single-point prediction.

Discussion
This work demonstrates the potential of a human serum Gln assay which requires only
microliter quantities of blood and can be executed in an hour. Notably, the presented sensor’s
detectable range corresponds to physiological Gln levels which fall between 200 and 1400
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µM222,223. As shown in Figure 7-6, the GFP response in CFPS reactions with human serum is linear
from 0 to 120 µM Gln and is estimated to be differentiable up to ~300 µM (Figure 7-6). However,
only 14% of the CFPS volume is the serum sample, such that the detection range for sample Gln
is estimated to be up to ~2100 µM Gln. Additionally, our previous work suggests the amount of
serum sample added to the CFPS sensor may be adjusted to any concentration up to 44% (v/v)252
which would further expand the assay’s Gln detection range. We anticipate that the optimal serum
volume percent determined during clinical validation will likely fall between 10% and 20%
because, for most patients, these volumes would produce a readout in the assay’s linear response
range. In this work, GFP was used as a reporter because of its high quantum yield, contributing to
excellent assay signal-to-noise. A point-of-care embodiment of this technology might include a
handheld fluorimeter to obtain assay readout or a reporter enzyme with colorimetric substrate, such
as beta-galactosidase.
Potential clinical applications for this sensor include optimizing cancer treatments which
target Gln metabolism. For example, treatment of Acute Lymphoblastic Leukemia involves
depleting circulating asparagine (Asn) and Gln with bacterial L-asparaginase237, but subsequent
patient Gln levels are not routinely monitored nor used to inform individual treatment regimens.
In addition, there are currently six clinical trials incorporating the use of a glutaminase inhibitor as
a treatment for patients with non-small cell lung cancer, renal cancer, colorectal cancer, melanoma,
myelodysplastic syndrome, and metastatic solid tumors. This assay may enable careful monitoring
of Gln during this treatment to ascertain optimal dosage and administration. Furthermore, shifts in
serum Gln levels may serve as a diagnostic marker for other maladies. For example, the onset of
sepsis and critical illness exhibits decreased plasma Gln levels221, possibly because Gln is a main
fuel source for the immune system. In contrast, chronic kidney disease, anorexia nervosa, and
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higher incidence of type 2 diabetes are associated with increased serum Gln levels222,223,226. The
CFPS-based assay developed in this work has the potential to mark the onset of such diseases and
assist in rehabilitating patients. While the assay performance data herein reported is compelling,
additional validation is needed prior to clinical use. For example, patient serum contains other
amino acids which could affect CFPS. We therefore initiated CFPS with excess Asn and aspartate
(Asp), which are integral to Gln metabolism (Figure 7-2), seeking to mitigate these potential serum
matrix effects. We discovered that excess Asn and Asp in CFPS is favorable to the Gln detection
assay. Interestingly, Asn enhances the signal strength of the CFPS Gln assay (Figure 7-7) while
Asp improves CFPS as an inhibitor of phosphoenolpyruvate carboxylase (Figure 7-7).
In addition to creating a compelling Gln assay, this work also suggests CFPS may be
engineered to rapidly screen inhibitors of enzymes. For example, Figure 7-4B indirectly reports
GLNS inhibition efficiency at varying MSO concentrations. While there are many possible
inhibition screens, one future example could be using CFPS reactions initiated with NDPs instead
of NTPs to serve as a rapid screening tool for inhibitors of nucleoside-diphosphate kinases, which
may be important in cardiovascular disease and cancer metastasis257.
The metabolic engineering approach presented in this work may also be useful for
optimizing protein expression yield or other desired products from cell-free reactions. Indeed,
many enzymes which likely retain activity in the lysate-based CFPS reactions consume precious
ATP superfluously. For example, GLNS, which is inhibited in this work, consumes ATP in the
process of synthesizing Gln. Notable early work demonstrated precedent when oxalate, an
inhibitor of phosphoenolpyruvate synthetase, was shown to increase CFPS expression yield due to
enhanced preservation of ATP258. Indeed, during the process of completing the work reported
herein, we learned that phosphoenolpyruvate carboxylase circumvents the production of ATP from
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PEP, and that its inhibition might improve CFPS performance. Accordingly, we identified Asp as
an inhibitor of this enzyme259 and observed that CFPS initiated with 12 mM Asp compared with
the conventional 2 mM Asp increased CFPS yield by 38% over a one-hour reaction (Figure 7-7).
The results reported herein demonstrate that using small-molecule inhibitors and amino acid
composition to engineer CFPS metabolism is a rich platform for CFPS performance optimization,
in addition to sensing and drug discovery.

Figure 7-7: CFPS of GFP at indicated initial Gln concentrations and 70 mM MSO. A. Reactions were
initiated with 0 mM Asparagine (Asn) and Aspartate (Asp) (circles), 2 mM Asn and Asp (squares),
or 6 mM Asn and Asp (diamonds), and 2 mM of other proteinogenic amino acids except glutamate
(Glu). B. Reactions were initiated with 0 mM Asn and 2 mM Asp (circles) or 2 mM Asn and 0 mM
Asp (squares), and 2 mM of other proteinogenic amino acids except glutamate. Data traces represent
n=2 independent cell-free reactions at each Gln concentration obtained after 1 hr CFPS. Lines
represent least-squares regression of data points to the Hill equation. The results presented here
demonstrate that Asn enhances the effect of Gln on CFPS expression yield in the presence of 70 mM
MSO. In contrast, Asp did not enhance the effect of Gln on CFPS expression yield. Possible
explanations for the effect of Asn on the Gln assay include the role of Gln and Asn in nitrogen
metabolism, and the activity of asparagine synthetase, which interconverts Asp and Gln to Asn and
Glu. C. CFPS of GFP with initial Gln concentrations as indicated on the graph. The CFPS reagents
included 70 mM MSO, 0 mM Asn, 0 mM Asp, 2 mM of other proteinogenic amino acids, and dialyzed
(circles) or not dialyzed (diamonds) E. coli extracts. Data traces represent n=2 independent cell-free
reactions at each Gln concentration obtained after 1 hr CFPS. D. CFPS of GFP with the indicated
initial Asp concentrations. Error bars represent one standard deviation for n=2 independent cell-free
reactions. Measurements were obtained after 1 hr CFPS.

94

A key feature of the E. coli-based CFPS diagnostic platform demonstrated herein is the
economy with which it can be deployed. Each sensor requires only 0.03 mL of CFPS and thus only
minor reagent costs. Compared with most current medical diagnostics, this represents a significant
cost reduction. With the cost of healthcare increasing at alarming rates, new technologies which
enhance the precision and efficiency of medical care at low cost are in high demand. Such
technologies may also increase availability to healthcare in underserved communities and the
developing world.
Importantly, the human serum sensor reported herein requires only 0.009 mL of serum,
which is equivalent to the amount of blood required by commercial, portable glucose meters used
by diabetics several times a day. While this initial work reports the use of human serum, we
previously reported CFPS-based sensors worked well in whole human blood at 20% (v/v)
concentrations240. Based on these reports, it is likely that 14% (v/v) whole blood (the volume % of
serum used in this work) would perform similarly and eliminate the centrifugation step needed to
separate serum. Finally, we have previously reported optimizing the lyophilization of CFPS
reagents for long-term shelf-stable storage and reported utility for sensing applications249.
Together, these advances suggest glucose-meter-like sensing capabilities for blood Gln
concentrations are possible in the near future239. Ultimately, cell-free protein synthesis biosensors
which rapidly and economically quantify metabolites and disease biomarkers at the point-of-care
have the potential to reduce medical costs, individualize treatment, and improve patient outcomes.

Conclusion
E. coli-based CFPS reactions retain amino acid metabolism, but the open reaction
environment facilitates metabolic engineering using small-molecule inhibitors and amino acid
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composition. We apply this approach to create CFPS reactions wherein the protein expression
yield is highly sensitive to the amount of Gln added through the sample of interest. Furthermore,
we demonstrate that this sensitivity is exhibited in the presence of human serum. The assay’s
detection range is ideally suited to sensing physiologically relevant Gln concentrations and could
provide a useful clinical tool to help individuals suffering from severe infection, anorexia nervosa,
chronic kidney disease, diabetes, and cancer. The metabolic engineering approach used to create
this sensor could also be applied to improve cell-free production, facilitate drug discovery, and
create economic point-of-care sensors of other clinical biomarkers.
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BIOMANUFACTURING AND BIOSENSING FOR TREATMENT OF ACUTE
LYMPHOBLASTIC LEUKEMIA WITH CELL-FREE PROTEIN SYNTHESIS

This chapter is an adaptation from the article by J. Porter Hunt, Kristen M. Wilding, R.
Jordan Barnett, Hannah Robinson, Mehran Soltani, Jae Eun Cho, Bradley C. Bundy entitled,
“Engineering cell-free protein synthesis for high-yield production and human serum activity
assessment of asparaginase – toward on-demand treatment of acute lymphoblastic leukemia”
published
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January

2020,

15,

1900294,

https://doi.org/10.1002/biot.201900294. JPH conceived and directed the work, and is grateful to
Kristen Wilding, R. Jordan Barnett, Hannah Robinson, Mehran Soltani, and Jae Eun Cho for their
contributions. JPH is especially grateful to R. Jordan Barnett for significant contributions to the
experimental validation of the concept.

Introduction
Acute lymphocytic leukemia (ALL) is the most common childhood cancer in the U.S. Over
the past several decades, survival rates have increased to >80%, in part because of the
incorporation of bacterial L-asparaginase (ASNase) into therapeutic regimens260. This treatment
strategy exploits the dependency of leukemic cells on exogenous asparagine (ASN) by reducing
the concentration of circulating ASN in the patient261. However, the high immunogenicity of
bacterial ASNases presents a significant challenge. Short half-lives may necessitate multiple
administrations weekly and patients quickly develop antibodies against the E. coli ASNase
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(colaspase), leading to inactivation of the enzyme in up to 60% of cases262. The second-line
ASNase treatment from Erwinia chrysanthemi (crisantaspase) provokes neutralizing antibodies in
about 33% of patients261. ASNase-neutralizing antibodies may occur asymptomatically, and recent
studies suggest improved patient outcomes if circulating ASNase levels are monitored during
treatment263, 264 so that additional therapeutics may be utilized.
Various methods for quantifying ASNase activity are used, but these generally require
toxic chemicals or complex chains of enzymes which may obscure ASNase kinetics6. In general,
these assays require strict cold-chain storage of reagents and standards. Cell-free protein synthesis
(CFPS) offers an alternative platform for ASNase activity assessment which presents multiple
advantages over traditional approaches. First, CFPS reactions can be rendered shelf-stable, thus
mitigating the need for cold-chain storage of assay components, enabling high-density storage and
facile use266, 267. Second, the CFPS platform provides an open reaction environment which may be
dynamically optimized268 and is reportedly robust against samples containing human blood269.
Already, CFPS biosensors have been employed to detect a variety of clinically and
environmentally relevant compounds267,

270-272

. These advantages could enable a CFPS-based

ASNase activity assay to be conveniently stored at clinics in a variety of locations worldwide and
easily deployed for on-demand processing of blood samples. Here we demonstrate the feasibility
of a rapid CFPS-based ASNase activity assay for high-throughput, low-cost assessment of ASNase
activity.
In addition to sensing ASNase activity, CFPS can also rapidly produce active ASNase for
on-demand therapeutic applications273. This capability could be especially valuable for scenarios
where storing shelf-stable CFPS reagents is preferred to maintaining a library of therapeutic
proteins, such as rural clinics or humanitarian outposts274, 275. Furthermore, on-demand ASNase
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production could provide hospitals with a versatile defense against ASNase shortages (at the time
this manuscript was submitted, Erwinaze (crisantaspase) was not available for purchase by
hospitals for at least one month due to a drug shortage)276. Ultimately, on-demand ASNase
production has the potential to lower costs and enable individualized treatment277, especially as
more diverse ASNase enzymes are approved for treatment of ALL278.
High-yield CFPS production of ASNase also facilitates protein engineering of ASNase.
While ASNase can be expressed in fermented whole cells, conservative expression techniques and
extensive purification279, 280 limit discovery and development. In contrast, CFPS features an open
reaction environment which facilitates dynamic optimization of critical components268, 281, 282,
monitoring of reaction progress283, 284, and simplified purification285, 286. Using CFPS, researchers
have site-specifically optimized protein PEGylation287 and immobilization288, and have enabled
cytotoxic therapeutic production268. Thus, techniques for improved CFPS expression of ASNase
may enable diverse advances for next-generation ASNase technologies.
Here we report enhancing CFPS crisantaspase production yields by 72% through
supplementing additional ASP at regular time intervals throughout the reaction. In addition, the
manifold functionality of E. coli CFPS systems is demonstrated with an in-house CFPS-based
ASNase activity assay to rapidly assess the activity of therapeutic crisantaspase in buffer, CFPS,
and human serum. This work suggests that shelf-stable E. coli CFPS reactions may be employed
on-demand to 1) synthesize biologics, 2) determine the activity for quality control and dosage
calculations, and 3) monitor therapeutic effectiveness during the treatment regimen. The
combination of therapeutic production and activity assessment introduces a concept of
multifaceted utility for bacterial cell lysates in modern medical treatment.
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Materials and Methods

8.2.1

Cell Extract Preparation

E. coli cell extract containing bacteriophage T7 RNA polymerase was prepared as
previously described287.

8.2.2

Cell-free Protein Synthesis of Crisantaspase

CFPS reactions were formulated in 96 well plates or 2 mL microcentrifuge tubes
(BioExpress, GeneMate). 25 volume percent cell extract was added to 12 nM plasmid DNA and
the following components: 10 to 20 mM magnesium glutamate (concentration optimized for
protein yield), 1 mM 1,4-diaminobutane, 1.5 mM spermidine, 40 mM phosphoenolpyruvate (PEP),
10 mM ammonium glutamate, 175 mM potassium glutamate, 2.7 mM potassium oxalate, 0.33 mM
nicotinamide adenine dinucleotide (NAD), 0.27 mM coenzyme A (CoA), 1.2 mM ATP, 0.86 mM
CTP, 0.86 mM GTP, 0.86 mM UTP, 0.17 mM folinic acid, and 2 mM of all the canonical amino
acids except glutamic acid, and incubated at 37 °C. CFPS reactions producing crisantaspase were
incubated at 30 °C shaking at 200 RPM, and selected reactions were supplemented with 2 uL 40
mM ASP every 30 min for 330 min, and a total reaction time of 7 hrs. Protein yield was quantified
with C14 leucine as previously described287. 4 uL CFPS containing C14-labeled protein was loaded
directly onto NuPAGE 4-12% bis-tris gel (Invitrogen) before electrophoresis in MES Buffer (50
mM MES [2-(N-morpholino)ethanesulfonic acid], 50 mM Tris base, 1 mM EDTA, 0.1% [w/v]
SDS) at 200 V for 35 minutes. The resultant gel was visualized with autoradiography as previously
described287. Plasmid used to express GFP and crisantaspase were reported previously286.
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8.2.3

CFPS-based Asparaginase Assay

CFPS-based ASNase assays were created using 65 uL CFPS reactions to synthesize GFP
in 96-well black assay plates (Corning®, Costar) as described above, with the exception that ASN
was omitted from the initial formulation. To create a standard curve correlating GFP production
to ASNase activity, different quantities of commercially produced E. coli ASNase (Biovendor)
were added to the reaction (ASNase activity levels tested were 0.19, 0.58, 0.96, 1.35, 1.73, 2.12
IU/mL). ASNase was suspended in water, 290 mOsM HEPES/PEG-400 buffer (100 mM HEPES,
180 mM PEG-400), or human serum (Gemini Bio-Products, West Sacramento, CA) prior to using
in the CFPS-based ASNase activity assay. Murine RNAse inhibitor (New England Biolabs,
Ipswich, MA) was added to reactions containing human serum at 1.0 or 0.8 IU RNAse inhibitor
per uL CFPS. GFP production was measured by fluorescence with the SynergyMX plate reader
(Biotek Instruments, Winooski, VT) every four minutes for three hours (485 nm excitation, 510
nm emission). CFPS expression yields were normalized to the yield of GFP produced in the
absence of ASNase. The data was then fit to a first-order exponential decay to form a standard
curve and both upper and lower 95% confidence intervals and prediction bands were determined
using Python to perform calculations. Functional limit of detection was calculated by subtracting
two times the standard deviation of reads with no ASNase activity from the average of these reads.
To test the activity of ASNase produced with CFPS, a CFPS-based ASNase activity assay
was performed as described above. The exception is that instead of adding commercial E. coli
ASNase, the CFPS product from the ASNase production reaction was directly added to the CFPSbased ASNase activity assay (5 uL to a 65 uL reaction). The specific activity was determined using
the standard curve above to determine activity and scintillation counting the C14-leucine-labeled
ASNase to determine ASNase concentration.
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Results

8.3.1

Asparagine-Supplemented CFPS for Improved Crisantaspase Expression

Our previous reports to synthesize active crisantaspase in E. coli-based CFPS reactions
resulted in lower expression yields, which was attributed to crisantaspase degrading the necessary
translation reactant ASN. Indeed, supplementing with additional ASN did improve crisantaspase
yields273. There is also evidence that the lysate in CFPS reactions (which contains all soluble
proteins from E. coli) synthesizes ASN. For example, GFP producing CFPS reactions initiated
with 0 mM ASN added showed similar expression yields as those initiated with 2 mM ASN (Figure
8-2A).

Figure 8-1: A. ASNase mechanism of activity and principle of inhibition by L-aspartate (ASP). B.
Depiction of the CFPS work-flow, including fermentation, lysis, and addition of critical
transcription/translation components. C. CFPS production of crisantaspase at standard reaction
conditions (2 mM ASP). D. Improved CFPS of crisantaspase with high ASP concentrations (17+ mM).
E. CFPS expression yield (bars) and specific activity (x) of crisantaspase under standard, initial, and
continuous ASP supplementation regimens. Continuously supplemented reactions (denoted by 17+
mM) were supplemented with an additional 2 uL 40 mM ASP every 30 min for 330 min. All reactions
were stopped after seven hours at 30 °C and 200 RPM. Error bars represent one standard deviation
for n=3 CFPS reactions.
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After careful inspection of the native E. coli amino acid biosynthesis pathways, we hypothesized
that the native E. coli asparagine synthetase retains enough activity in the cell extract to supply the
GFP-producing CFPS reactions with the necessary ASN. Concomitantly, we hypothesized that
increasing the concentration of ASP in CFPS producing crisantaspase would provide higher
concentrations of both ASN and ASP in the reaction environment by 1) supplying the native
asparagine synthetases with abundant substrate to be converted to ASN and 2) inhibiting the ASNdegrading activity of newly synthesized crisantaspase289.
Leveraging the accessibility of the CFPS reaction environment, CFPS reactions producing
crisantaspase with an initial concentration 17 mM ASP were compared to CFPS reactions with the
conventional 2 mM initial ASP concentration. Reactions initiated with 17 mM ASP resulted in a
46% improvement in crisantaspase expression yield over the standard CFPS reaction formulation
(Figure 8-1). Because ASP may be continually degraded throughout the CFPS reaction, we
hypothesized that supplementing the CFPS reaction with ASP at regular intervals could further
improve crisantaspase expression yield. Reactions initiated with 17 mM ASP and supplemented
with 2 uL of 40 mM ASP every 30 min for 330 min achieved a 72% improvement in crisantaspase
expression yield over the standard CFPS formulation (Figure 8-1E). Production of full length
crisantaspase was verified by gel electrophoresis and autoradiography (Figure 8-2B). These
synthesis yields could produce a single child’s IV (intravenous) dose from ~40 mL CFPS265. While
demonstrating the purification necessary to utilize this technology for on-demand treatment
pertains to future work, recent advances in intein-mediated bio-separations290 and endotoxin-free
CFPS286 are promising. The specific activity of CFPS crisantaspase was also determined using a
new in-house CFPS-based assay that is reported for the first time below (Figure 8-1E).
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Figure 8-2: A. CFPS expression of GFP in RFU with 0 mM and 2 mM initial L-asparagine. Error
bars represent one standard deviation for n=2 CFPS reactions. B. Denaturing gel electrophoresis of
C14-labeled crisantaspase producing CFPS reactions with autoradiogram overlay; from left to right,
lane 1: protein ladder, lane 2: 2 mM ASP CFPS, lane 3: 17 mM ASP CFPS, lane 4: 17+ mM ASP
CFPS. All lanes were loaded with 4 uL CFPS. For reference, the molecular weight of a crisantaspase
monomer is 35.1 kDa.

8.3.2

E. coli CFPS Asparaginase Assay

Noting that ASN metabolism in CFPS directly impacts crisantaspase expression yield, we
hypothesized that CFPS reactions could be formulated such that protein yield becomes an indicator
of ASNase activity in the reaction (Figure 8-3). This concept for a CFPS ASNase activity assay is
supported by recent work sensing amino acids using CFPS291,292. To test this hypothesis, GFPexpressing CFPS reactions were initiated with increasing amounts of commercial E. coli ASNase.
As expected, the resultant GFP expression yield was a function of ASNase activity (Figure 8-3B).
This effect was observed after as little as 20 minutes but was more pronounced after 30 minutes.
Not unexpectedly, the sensitivity of the assay decreased significantly when reactions were initiated
with the conventional 2 mM ASN rather than omitting ASN from the initial formulation. Notably,
adding the initial 2 mM ASN allowed activity assessment at higher titers of ASNase (Figure 8-4).
A standard curve was fit to the data to further quantify the effect of ASNase activity on GFP
production in CFPS after aggregating the data from three independent reaction series. These data
follow a first-order exponential decay, with a “time” constant of 0.728 ± 0.018 (Figure 8-3B). The
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fit obtained by the nonlinear regression yielded a 0.97 coefficient of determination and 95%
confidence bands as shown. 95% prediction bands are also included to illustrate the confidence of
using this plot to determine ASNase activity in IU/mg from a single activity assay. The ASNase
activity assay was repeated by adding E. coli ASNase suspended in 290 mOsM HEPES/PEG-400
buffer to CFPS to a final buffer concentration of 47 volume percent (Figure 8-5).
Before using this CFPS activity assay to quantify ASNase activity in human serum, CFPS
of GFP was tested in the presence of increasing volume percent human serum. Reactions with 20%
and 40% serum did not produce fluorescence above background (Figure 8-6, red line). We and
others have previously reported findings which suggest that human blood contains appreciable
RNAse activity269,

293

, and we hypothesized that serum RNAse activity was responsible for

decimating CFPS GFP yield. Accordingly, we added 1.0 IU murine RNAse inhibitor294 per uL
CFPS, which rescued CFPS production of GFP in the presence of 20% and 40% human serum
(Figure 8-6, blue bars). Next, human serum containing increasing amounts of E. coli ASNase was
added to CFPS without ASN to 44 volume percent serum and 0.8 IU RNAse inhibitor per uL CFPS.
The response of the resultant ASNase assay also followed first-order exponential decay with a
“time” constant of 2.46 (Figure 8-6). This result suggests that engineered CFPS is a rapid,
economical, and potentially on-demand ASNase activity assay to verify circulating ASNase
activity in patients undergoing ALL treatment. A drop in measured activity could then drive dosage
or other regimentation adjustments.
In addition to monitoring circulating ASNase activity, the CFPS-based ASNase activity
assay could also be employed to verify the activity of ASNase after synthesis for quality control.
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Figure 8-3: A. Depiction of L-asparagine (ASN) depletion by L-asparaginase (ASNase) in CFPS
reactions, and subsequent reduction in GFP expression yield. B. Standard curve of CFPS-based
ASNase activity assay after 52 min CFPS reaction. Black line: regression fit. Dashed blue lines: 95%
confidence bands, dashed red line: 95% prediction bands. GFP yield in the presence of ASNase
activity is normalized to GFP yield in the absence of ASNase activity. The standard curve is generated
by regressing normalized CFPS GFP expression yield as a function of ASNase activity to the first
order exponential decay function with a “time” constant of 0.728 ± 0.018. Also reported is the 95%
confidence bands indicating confidence in the regression fit and the 95% predication band indicating
confidence in using the regression fit to determine specific activity from a single activity assay. The
functional limit of detection is 0.07 IU/mL.

Figure 8-4: Response of CFPS reactions producing GFP initiated with 2 mM L-asparagine (ASN)
and the indicated E. coli L-asparaginase activity. This reaction format contrasts with those which
obtain higher sensitivity to ASNase activity because they are initiated without ASN. GFP yield in the
presence of the indicated ASNase activity is normalized to GFP yield in the absence of ASNase
activity. Reactions were performed in duplicate and each reaction is represented by a data point.
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Figure 8-5: A. Results of the CFPS asparaginase assay with increasing concentrations of commercial
E. coli asparaginase suspended in 290 mOsM HEPES/PEG-400 buffer. Final HEPES/PEG-400 buffer
concentration in all CFPS reactions is 47 volume percent. Error bars represent one standard
deviation for n=2 CFPS reactions. B. CFPS reactions producing GFP in the presence of E. coli
ASNase and ASP. Reported conditions include 0 IU/mL ASNase (no ASNase added), 1.54 IU/mL
ASNase, and 1.54 IU/mL ASNase + 6.5 mM ASP. Comparing 1.54 IU/mL and 1.54 IU/mL + 6.5 mM
ASP curves confirms the inhibitory effect of ASP supplementation on ASNase activity. NP control
tests for the impact of CFPS machinery and possible reaction products if added to a CFPS reaction
producing GFP. As such, for the NP control 5 uL of a cell-free reaction product (where no plasmid
was added such that no protein expression was templated) was added to a second CFPS reaction
producing GFP. This verifies no underlying inhibitory effect if CFPS product is added to the CFPSbased ASNase activity assay. Error bars represent one standard deviation for n=2 CFPS reactions.

This is particularly important for distributed, on-site synthesis even in remote locations,
which is supported by recent work reporting the ability of CFPS to produce therapeutic
crisantaspase from lyophilized reagents273. We thus employed the CFPS-based ASNase activity
assay to measure the activity of in-house CFPS-produced crisantaspase immediately following its
production. The specific activity of CFPS-produced crisantaspase was 71.0 IU/mg, 66.8 IU/mg,
and 58.6 IU/mg for 2 mM, 17 mM and 17+ mM reactions, respectively (Figure 8-1). The decrease
in activity with increasing ASP concentration is expected, and control CFPS-based ASNase
activity assays using a commercial E. coli ASNase stock demonstrated lower activity when ASP
was added (Figure 8-5B). Thus, the impact of ASP concentrations should be considered before
testing to obtain the most accurate specific activity results. Because dosage is best determined by
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ASNase activity rather than ASNase concentration, this assay provides a simple low-cost method
to enable activity-based dosage determinations with distributed, on-site, on-demand production
capabilities.

Figure 8-6: A. Effect of human serum and murine RNAse inhibitor on CFPS production of GFP. Red
line represents CFPS yield at 0, 20, and 40 volume percent human serum in the absence of RNase
inhibitor. Blue bars represent CFPS yield in the presence of 1.0 IU RNAse inhibitor per uL CFPS at
0, 20, and 40 volume percent human serum. Error bars represent one standard deviation for n=2
CFPS reactions. B. Response of GFP-producing CFPS ASNase activity assay in the presence of 44
volume percent human serum and 0.8 IU RNAse inhibitor per uL CFPS. GFP yield in the presence
of ASNase activity is normalized to GFP yield in the absence of ASNase activity. Normalized
fluorescence data were regressed to a first order exponential decay function using least squares to
obtain a “time” constant with respect to ASNase activity of 2.46. CFPS reactions were executed in
duplicate, with each data point representing one reaction. Ribbon diagram of murine RNAse
inhibitor.

Discussion
The ASNase assay reported in this work is remarkably sensitive, rapid, and economical.
Because ASNase activities as low as 0.1 to 0.2 IU/mL are reported sufficient for therapeutic
efficacy, the assay’s functional limit of detection of 0.07 IU/mL is applicable for monitoring and
optimizing treatment of ALL295. This assay requires 30+ minutes for optimal readout but can
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produce results in as few as 20 minutes. In addition, the assay could be formulated as a just-addsample, shelf-stable lyophilized mix due to the success of lyophilized CFPS reagents273. The
procedure is also low-cost: one test well of ASNase assay CFPS reaction costs about $0.14296, for
a total cost of <$2.00 for each test if a complete standard is run in parallel. Furthermore,
streamlined cell extract preparation procedures are making CFPS technology increasingly
available to prospective laboratories297. Quantifying ASNase in 290 mOsM HEPES/PEG-400
buffer suggests that the assay will be robust in solutions used to stabilize ASNase (Figure 8-5).
The quantification of ASNase activity in human serum is especially promising because: 1) this is
the first time to our knowledge that active CFPS has been reported in the presence of human serum,
and 2) detecting ASNase activity in the presence of 44% serum suggests that this assay could help
improve ALL treatment by monitoring patient serum ASNase activity. The rapid, sensitive, and
economical nature of this assay makes it an especially suitable candidate for development as an
on-demand indicator.
The open CFPS environment enabled facile ASP supplementation to achieve the herein
reported 72% improvement in crisantaspase yield. The portable nature of the synthesis platform
may become especially useful for personalized on-site treatments or treatment in remote locations.
Recently reported endotoxin-free E. coli CFPS systems are an important step toward on-demand
administration of biologics, such as crisantaspase synthesized herein273. The improvement in yield
by ASP added throughout the CFPS reaction suggests that initial ASP is consumed by native
asparagine synthetases during CFPS, and further optimization of ASP supplementation may yet
improve expression. However, each added bolus increases the total reaction volume and decreases
the concentrations of other active components. Reliable mathematical models of CFPS would
facilitate more precise prescription of the optimal supplementation regimen, such as variable
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supplementation frequency or additional compounds to be supplemented. Because crisantaspase
also deaminates glutamine298,
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, further improvement in crisantaspase expression might be

achieved by adding glutamine in concert with ASP. Indeed, these concepts may lead to unique
CFPS

formulations,

including

engineered

amino

acid

concentrations

and

dynamic

supplementation regimens, for maximal expression yield of target proteins300.

Conclusion
In conclusion, we have demonstrated that ASP-supplementation to crisantaspaseproducing CFPS significantly enhances production yields. In addition, a new CFPS-based ASNase
activity assay is reported that is inexpensive, sensitive, and functions in 44 volume percent human
serum. The assay has application for quality control and dosage calculations following on-site, ondemand production of crisantaspase, and the potential for monitoring ASNase activity in patient
blood to ensure optimal ASNase treatment of ALL. Overall, this work further demonstrates the
multifaceted application potential of cell-free protein synthesis systems.
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9

CONCLUSIONS AND FUTURE WORK

This work documents exciting advances to the field of cell-free protein synthesis (CFPS).
First, an endotoxin-free CPFS platform was created for simplified purification and potential ondemand production of biotherapeutics. Next, autoinduction media was employed for streamlined
preparation of endotoxin-free CFPS. Additionally, the oxygen-dependence of E. coli CFPS was
elucidated, leading to the introduction of novel “hydrofoam” and oxygen-headspace bioreactors
for improved production yields of therapeutic proteins. We anticipate that these advances could
facilitate magistral production of biologics in the hospital setting. A rapid biosensor of estrogenic
chemicals was created and validated in human blood and urine. The molecular mechanism of this
protein construct was elucidated and the assay readout was optimized with mathematical
simulations and CFPS. Then, CFPS was metabolically engineered to create a biosensor of Lglutamine, the most abundant amino acid in the body. This technology may help facilitate and
precision therapy for cancer treatments which target glutamine metabolism. Finally, a synergistic
platform was developed for potentially treating Acute Lymphoblastic Leukemia wherein CFPS
was engineered to both produce the therapeutic protein crisantaspase, and monitor its activity in
the presence of human serum for improved, even personalized treatment of the disease. It is
anticipated that these advances will contribute to the eventual improvement of diagnosis and
treatment of diseases using CFPS.
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